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Abstract 
Neuronal ceroid lipofuscinoses make up the most common group of neurodegenerative 
diseases amongst children. Classified into 13 distinct variants (CLN1-13), extensive 
research has been undertaken in the previous decade in order to understand the 
pathogenesis of the variations of the disease, however, very little is still known about the 
variant, CLN7. The aim of this project was to utilise existing techniques in neural 
differentiation in order to deduce any differences in metabolism and autophagic flux 
between neural progenitor cells and further differentiated CLN7 patient cells compared 
to those of control. A stepwise neural differentiation protocol was implemented in order 
to differentiate human induced pluripotent stem cells to NPCs and subsequently neurons. 
A range of qPCR targets relating to pluripotency, metabolism and inflammation were 
selected in order to deduce changes in gene expression in both NPCs and iPSCs. 
Quantitative analysis provided insight and demonstrated a clear metabolic shift toward 
glycolysis in NPCs of CLN7, whereas controls favoured oxidative phosphorylation, evident 
by an increase in oxidative stress, a consequence of OXPHOS due to increased ROS 
production, indicating mitochondrial dysfunction. An upregulation in the inflammatory 
pathway, NFkB1 was evident, indicating an increase in inflammation in CLN7 NPCs. 
Western blot analysis provided insight into an impairment of autophagy through 
accumulation of p62 as well as activation of p70, a downstream target of the mTORC1 
pathway. The results obtained during the project provide a new insight into the 
pathogenesis of the CLN7 and potentially the pathways relating to the disease resulting in 
neurodegeneration.  
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1.0 Introduction 
1.1 Neuronal Ceroid Lipofuscinosis  
The Neuronal Ceroid Lipofuscinoses (NCLs), commonly referred to as Batten Disease, are 
classified as lysosomal storage disorders (LSDs) and constitute the most common 
autosomally recessive group of inherited neurodegenerative disorders among children 
(Cárcel-Trullols, Kovács and Pearce, 2015), with current estimates suggesting an incidence 
of 1-4 in 100,000 live births worldwide (Rakheja and Bennett, 2018). Current research has 
demonstrated mutations in distinct genes, CLN1-8 and CLN9-14. Of these various 
associated proteins, most of them have been localised within lysosomes (CLN1, CLN2, 
CLN3, CLN5, CLN7, CLN10, CLN12 and CLN13), however CLN6 and CLN8 have been 
established to localise within the Endoplasmic reticulum, whilst it has been proposed 
CLN3, CLN7 and CLN12 are lysosomal transmembrane proteins (Kollmann et al., 2013) 
(see table 1).  
Table 1: Comprehensive list of varying NCL disorders, related protein, subcellular localisation and their function (Cárcel-
Trullols, Kovács and Pearce, 2015).  
NCL Chromosome Protein Subcellular 
localisation 
Function 
CLN1 1p32 Palmitoyl protein 
thioesterase 1 (PPT1), 
soluble protein composed of 
306 amino acids.    
Lysosomal matrix, 
Endoplasmic reticulum, 
extralysosomal vesicles 
and presynaptic areas 
within neurons.   
Associated to endo and 
exocytosis in recycling of 
synaptic vesicles. Also 
has role during 
apoptosis. 
CLN2 11p15 TPP1 Endoplasmic reticulum 
and lysosomal matrix. 
Linked to 
macroautophagy, 
endocytosis and TNF-α-
induced apoptosis. 
CLN3 16p12 Lysosomal transmembrane 
protein 
Endosomal/lysosomal 
membrane 
Unknown. 
CLN4 20q13.33 Cysteine string protein Cytosolic, associated to 
synaptic vesicles in 
neurons, vesicular 
membranes and 
secretory granules in 
exo/endo/neurocrine 
cells. 
Function is fully rescued 
by α-synuclein, involved 
in presynaptic endo and 
exocytosis. 
CLN5 13q22 Soluble lysosomal protein Matrix of the lysosome. Unknown 
10 | P a g e  
 
CLN6 15q21 Transmembrane protein of 
ER 
Endoplasmic reticulum 
membrane. 
Unknown. 
CLN7 4q28 MFSD8, lysosomal 
membrane protein 
Lysosomal membrane. Unknown. 
CLN8 8q23 Transmembrane protein of 
ER 
Endoplasmic 
reticulum/ER-Golgi 
intermediate 
compartment 
membrane. 
Unknown. 
CLN9  Unknown protein Currently unknown. Unknown. 
CLN10 11p15 Cathepsin D Lysosomal matrix and 
extracellular. 
 
CLN11  Progranulin/Proepithelin/ 
Acrogranin  
Extracellular. Unknown. 
CLN12  ATPase13A2/KRPPD/PARK9/
HSA9947/RP-37C10.4 
Lysosomal membrane 
and multivesicular 
bodies. 
Unknown.  
CLN13  Cathepsin F Matrix of the lysosome. Unknown 
CLN14  Potassium channel 
tetramerization domain-
containing protein 7 
(KCTD7) 
Cytosolic and also 
partially associated to 
the plasma membrane.  
Unknown. 
 
Prior to the improvement of genetic technologies and thus the discovery of the NCL 
associated causative genes, NCL disorders were classified vis-à-vis age of onset and 
ultrastructural abnormalities.  
NCLs are defined as lysosomal storage disorders (LSDs), with the accumulation of this 
material attributed to impaired autophagy (Getty and Pearce, 2011). The storage material 
has been analysed immunohistochemically, in which a few extremely hydrophobic 
proteins were detected within the storage material consisting of subunit c of 
mitochondrial ATP synthase or sphingolipid activator proteins A and D (Kousi et al., 2009) 
(Rakheja and Bennett, 2018). This storage material accumulates in lysosomes within the 
cytosol of neurons as well as non-neuronal cells such as skin adnexal epithelial cells and 
endothelial cells, characterised by a heterogenous origin (Cárcel-Trullols, Kovács and 
Pearce, 2015) . Commonly, this accumulated material is autofluorescent and is positive 
for; Luxol fast blue (stains lipoproteins in the myelin sheath), periodic acid-Schiff (stains 
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polysaccharides, glycoproteins and glycolipids), Ziehl-Neelsen acid-fast stain (stains 
mycolic acids) and Sudan black (stains neutral triglycerides and lipoproteins) (Cárcel-
Trullols, Kovács and Pearce, 2015). It has been hypothesised that the accumulation 
mechanistic nature of the ceroid lipopigments in NCLs may be the result of an ancillary 
process, yet this would not elucidate the nature and functions of the NCL-causing gene 
products (Geraets et al., 2016) (Cárcel-Trullols, Kovács and Pearce, 2015). 
Ultrastructural analysis has been a key feature in the diagnostic procedure for NCL 
affected patients. It has been apparent that the accumulated storage inclusions occur not 
only in the central nervous system (CNS), but also within the peripheral nervous system. 
Indeed, it has been shown that the accumulation occurs within; Schwann cells, 
fibroblasts, conjunctival epithelial cells, smooth muscle cells, skeletal muscle cells, 
endothelial cells, trophoblastic cells, peripheral blood lymphocytes and eccrine sweat 
gland epithelial cells (Rakheja and Bennett, 2018). The inclusions within the two latter cell 
types are especially poignant as they allow for the least invasive procedure in order to 
carry out ultrastructural examination. The presence of storage material in trophoblasts 
has allowed for prenatal diagnosis within the first trimester of biopsies from chorionic 
villi. When observed using transmission electron microscopy, this storage material is 
observed as cytosomes – cytoplasmic storage bodies which may be membrane-enclosed, 
implicating lysosomal storage (Anderson et al., 2006). The implication of lysosomal 
storage has been enforced by the activity of lysosomal acid phosphatase with the 
associated storage material.  
Four ultrastructural morphological patterns correlate with the various types of NCL 
disorders, including; granular osmiophilic deposits (GRODs) relating to INCL, curvilinear 
profiles (CLPs) relating to LINCL, fingerprint profiles (FPPs) relating to JNCL and finally 
rectilinear profiles (RLPs) (Aberg et al., 1998). Biochemical analysis has been performed 
on each of these morphological patterns, the results show that GRODs are associated 
with an accumulation of sphingolipid activator proteins A or saposins A, whereas CLPs, 
FPPs and RLPs are all associated with an accumulation of subunit C of mitochondrial ATP 
synthase (Rakheja and Bennett, 2018). It has been established that GRODs are 
homogenous, membrane-enclosed or finely granular rounded bodies, measuring up to 0.5 
microns in diameter and often form aggregates that measure up to 5 microns in diameter 
(Bennett and Rakheja, 2013). CLPs are membrane-enclosed and have the appearance of 
C- or S-shaped dark and light alternating lines that exist electron densely, freely within the 
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cytoplasmic matrix, measuring 1.9-2.4nm in thickness. FPPs are bound, compact, usually 
membrane-enclosed, stacks of paired parallel dark lines, often resembling fingerprints. It 
has been shown that each pair of these dark line’s measures approximately 7.6-9.6nm in 
thickness, with each adjacent pair separated by a distance of 3-4nm. Each dark line within 
these pairs are separated from one another by a lucent zone of 1-3nm (Anderson et al., 
2006). RLPs are generally stacks alternating light and dark lines measuring 2.8-3.8nm in 
thickness. It has been noted that mixed patterns of FPPs with CLPs or RLPs can occur 
within the same cytosome (Rakheja and Bennett, 2018). Each variant of neuronal ceroid 
lipofuscinosis produces a distinct morphological abnormality, with several variants 
displaying overlapping abnormalities (see table 2) and plays a role in determination of 
NCL variant along with genetic testing (Bennett and Rakheja, 2013). 
 
Table 2: Table 2: The Ultrastructural morphological abnormalities of storage material in the different NCL variants 
(Rakheja and Bennett, 2018)  
Ultrastructural Abnormality  NCL Variant 
Rectilinear profiles (RLP) CLN5, CLN6, CLN7 
Curvilinear Profiles (CLP) CLN2, CLN5, CLN6, CLN7, CLN8, CLN9 
Fingerprint Profile (FPP) CLN3, CLN4A, CLN5, CLN6, CLN7, CLN9 
Granular Osmiophilic Deposit (GROD) CLN1, CLN4B, CLN9, CLN10 
 
Presently, no cure has been developed for any variant of the NCLs, with current therapies 
aimed at improvement in quality of life for patients rather than viable treatment. Enzyme 
replacement therapy whereby a recombinant human tripeptidyl peptidase-1 cerliponase 
alpha (Brineura®) has been approved in CLN2 patients who have reached the ages of 
three years old and older by the Food and Drug Administration in the USA (Geraets et al., 
2016). This treatment has also been approved for CLN2 patients of all ages by the 
European Union. Other than this experimental therapy, drugs that dissipate symptoms 
such as epileptic seizures and mental health disorder are readily available, providing an 
insight into the importance in the understanding of the disease and progression of viable 
therapies (Geraets et al., 2016).   
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1.2 CLN7 Disease 
CLN7 disease is an autosomally recessive neurodegenerative disorder with onset during 
late infancy, caused by a mutation in the MFSD8 gene (Kousi et al., 2009). The MFSD8 
gene encodes for a polytopic lysosomal membrane glycoprotein, CLN7, of unknown 
function, in which patients of variant infantile neuronal ceroid lipofuscinosis are deficient 
(Sharifi et al., 2010). CLN7 disease begins to exhibit symptoms of mental and motor 
regression, seizures, ataxia and myoclonus, which lead to premature death within the first 
two decades of life, with patients becoming symptomatic between the ages of 1.5 and 5 
years old (Kousi et al., 2009). Various independent studies using methods such as 
proteomic analysis of purified human and rat tritosomes, immunoblotting of mouse liver 
tritosomes and co-localisation studies in hippocampal neurons have been performed to 
show the localisation of the endogenous protein, with several independent studies 
showing the glycoprotein localises in lysosomal membranes (Sharifi et al., 2010). 
 CLN7 is relatively unknown but has been shown to share sequence homologies with the 
drug: H+ antiporter family DHA1 of the major facilitator superfamily (MFS) of transporter 
proteins (Danyukova et al., 2018)(Sharifi et al., 2010). MFS transporters are the largest 
superfamily of secondary transporters found within the biosphere. They have been found 
to be distributed ubiquitously throughout almost all organismal phyla in current research 
(Quistgaard et al., 2016). The presence of these transporters has been found within 
bacteria, playing a vital role in the uptake of nutrients and removal of damaging 
compounds. Human models of MFS transporters demonstrate similar functions to those 
found in bacteria, such as nutrient absorption within the gastrointestinal tract and 
clearance of deleterious products within the renal and hepatic systems (Quistgaard et al., 
2016). This suggests that MFS transporters are evolutionary conserved throughout most 
currently recognised life-forms, from single cell organisms to complex biological systems 
found in humans. However, there have been evolutionary features found in human 
superfamily transporters unseen in other organisms that aid in the transport of nutrients, 
metabolites, signalling molecules and interactions of substrates between cells and 
between intracellular substrates (Saier et al., 1999). These additional features within 
humans have led to their implications in the mechanisms of diseases such as cancer and 
metabolic disorders; thus, leading to MFS transporters becoming potential targets for 
future drug therapies. Within current literature there are three recognised variants of 
MFS transporters including; uniporters, symporters and antiporters. Uniporters are 
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unique in the fact they require no external energy; however, they can only transport 
single substrates, which are generally transported down their concentration gradient 
(Quistgaard et al., 2016). Symporters are able to transport ion coupled substrates across a 
membrane in a single direction, whereas antiporters are able to sequentially transport 
two different substrates across a membrane in opposing directions. Symporters and 
antiporters are diametrically opposed to uniporters as they are able to utilize the energy 
stored within the concentration gradient of their ion coupled substrate and co-substrate, 
respectively, allowing for the transport of substrates against their concentration gradients 
(Quistgaard et al., 2016).  
 
RT-PCR has shown that Mfsd8 mRNA had a 12 and 6.4-fold change in abundancy in 
neurons than in astrocytes and microglial cells respectively, during analysis of rat cultures. 
It was found that Mfsd8 transcripts were more abundant in the hippocampus than in the 
cortex and midbrain by a factor of 2.4 and 5 times respectively, within the same study 
(Cárcel-Trullols, Kovács and Pearce, 2015). It has been shown through extensive 
biochemical studies that CLN7 colocalises with various lysosomal markers. Siintola et al. 
proved in transfected COS-1 cells, that HA-tagged wild type and mutant CLN7 colocalises 
with the Lysosomal-associated membrane protein 1 (LAMP1) (Siintola et al., 2007). The 
results of this study were reinforced by the work of Shariffi et al. as it was shown that 
endogenously expressed CLN7 and LAMP1 colocalised within the hippocampal neurons of 
mice (Sharifi et al., 2010). In CLN7 disease, 30 or more missense, nonsense and frameshift 
mutations in the MFSD8 gene have been identified which result in a relative uniform 
manifestation of variant late-infantile NCL, with only two exceptions. The nature of these 
mutations has been discussed at length, however the NCL phenotype resulting from the 
various mutations has been associated with a complete loss in function of the CLN7 
protein (Mohammed et al., 2017). An extensive study by Brandenstein et al. showed that 
a deletion of Cln7/Mfsd8 exon 2 leads to a complete loss of the CLN7 encoded 
glycoprotein.  
An in vivo study was undertaken in which Cln7 KO mice, carrying the European 
Conditional Mouse Mutagenesis (EUCOMM) tm1d allele were generated via Cre-
mediated recombination of the floxed exon 2 of the murine Cln7/Mfsd8 gene 
(Brandenstein et al., 2016). Genotyping the homozygous Cln7 KO mice and validation of 
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the loss of exon 2 was carried out, with both triplex polymerase chain reaction (PCR) and 
quantitative real-time PCR establishing the absence of exon 2 within the Cln7 KO mice. 
Sequence analysis of cDNA derived from the brain, kidney and liver of the Cln7 KO mice 
revealed that a loss of exon 2 culminated in the complete loss of nucleotides 67-115 in 
the coding sequence of the Cln7 mRNA (Brandenstein et al., 2016).  
The mammalian target of rapamycin 1 pathway, mTORC1, is known to regulate cell 
metabolism in response to amino acid stimuli. A study by Danyukova et al. sought out to 
show whether the loss of Cln7 in KO mice leads to an inactivation/activation of the 
mTORC1 pathway (Danyukova et al., 2018). The phosphorylation downstream target of 
mTORC1, S6 ribosomal protein (hereafter referred to as S6) was monitored in response to 
protracted starvation conditions in wild-type and Cln7 KO MEFs (Danyukova et al., 2018) 
(Xiao et al., 2009). It was found that both cell types exhibited similar responses to 
starvation, with complete inhibition of S6 observed at 2h followed by recovery of S6 
phosphorylation occurring at 4h with gradual increase following. However, it was found 
that at time points of 8h and 12h the levels of phosphorylated S6 was markedly 
decreased in Cln7 KO MEFs in comparison to their wild-type counterparts, indicating 
impairment of mTORC1 activation during extended starvation (Danyukova et al., 2018). 
The same study found that loss of Cln7 did not affect autophagic flux. Both Cln7 KO MEFs 
and their wildtype counterparts were exposed to bafilomycin A1, an inhibitor of 
lysosomal acidification and thus lysosomal degradation of cellular products. Western blot 
analysis of both LC3-II and p62 demonstrated comparable levels of both autophagic 
markers in both cell types (Danyukova et al., 2018). 
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1.3 Induced Pluripotent Stem Cells (iPSCs)  
The term ‘stem cells’ encompasses a subset of cells that possess the ability of self-
renewal, referring to the cells ability to perform multiple divisions whilst able to maintain 
an undifferentiated state, whilst also possessing the capability to differentiate along 
different cell lineages (Drozd et al., 2015). Stem cells are generally categorised into two 
main groups based on their capacity for self-renewal and plasticity (often referred to as 
the cells potency); “embryonic stem cells” and “non-embryonic stem cells”- also referred 
to as adult/somatic stem cells (Menon et al., 2016). Before the introduction of induced 
pluripotent stem cells, embryonic stem cells (ESCs) were studied intensively for their 
ability to differentiate into any cell type in the body. ESCs extracted from the early 
embryos of mice (mESCs), were the first cell type isolated which displayed pluripotent 
properties. In 1981, Evans and Kaufman and Gail R. Martin, independently described the 
first successful formation of mESCs cultures deriving from mouse blastocysts, as reviewed 
by Menon et al in 2016.  (Menon et al., 2016).  In 1998, Thomson and his colleagues 
progressed with their research into ESCs and successfully cultured human ESCs from 
blastocysts of human embryos, produced via in vitro fertilisation (IVF) as reviewed by 
Malik and Rao in 2013. (Malik and Rao, 2013). 
ESCs possess the unique characteristic of self-renewal, the ability to perpetually divide, 
whilst continuing to maintain an undifferentiated state, however they retain the capacity 
to differentiate into all three germ layers (ectoderm, mesoderm and endoderm), with this 
ability termed as totipotent  (Sridharan and Plath, 2008). Following fertilisation, 
totipotent cells mature into pluripotent cells, more specialised cells that maintain the 
ability to self-renew and differentiate into all germ layers down various cell lineages 
(figure 1). The pluripotent cells are responsible for tissue repair, growth and maintenance 
(Hu, 2014). 
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Figure 1: Cell fate of pluripotent stem cells 
Figure 1: Following successful fertilisation, ESCs enter a totipotent state, retaining the ability to 
develop all three germ layers along with cells of the placenta and embryonic tissues. Pluripotent 
cells maintain self-renewal and are able to differentiate through to the three germ layers and thus 
various cell lineages. These cells are more specialised within the blastocyst stage. Prior to 
differentiation into somatic cell types, multipotent cells are undifferentiated and found within 
postnatal tissues with a limited ability for self-renewal and are committed in to cell lineages 
dependent on the germ layer (Menon et al., 2016). 
Non-embryonic adult/somatic cells are found within postnatal tissues and exist in an 
undifferentiated, multipotent state with a more specialised nature of their cell types. 
Their ability to self-renew is limited and also vary in the degree of their plasticity 
potential, with these cell types committed to specific lineage differentiation (Malik and 
Rao, 2013).  
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Research laboratories have implemented the use of human and mouse embryonic stem 
cells in disease modelling and for the potential use in therapeutic approaches. Though 
they provide researchers with an unprecedented ability for in vivo disease modelling in 
vitro, the ethical issues surrounding embryonic stem cells has been an ever present and 
increasing obstacle for medical progression. However, the recent advancement in 
induced pluripotent stem cell generation and use may provide a solution to the many 
ethical and moral considerations of embryonic stem cells.  
In 1958, a study carried out by Gurdon et al. demonstrated a cell’s ability to re-instate 
pluripotency during end stage development via nuclear transcription. This technique was 
originally developed by Briggs and King, demonstrating successful nuclear reprogramming 
via the transplantation of nuclei of epithelial cells of the intestines from feeding tadpoles 
into enucleated eggs, which progressed into the development of healthy tadpoles, as 
reviewed by Sridharan and Plath in 2008 and later in 2016 by Menon at al.(Menon et al., 
2016) (Sridharan and Plath, 2008). This initial somatic cell nuclear transfer implied the 
presence of key factors responsible for induction and/or maintenance of pluripotency, 
producing the scaffold for the future breakthroughs in cellular reprogramming. In 2006, 
Takahashi and Yamanaka demonstrated the successful reprogramming of differentiated 
human somatic cells into a state of pluripotency through the retrovirus-mediated 
transfection of the transcription factors Oct3/4, Sox2, c-Myc and Klf4 (see figure 2) 
(Takahashi et al., 2007). The generation of iPSCs using these factors, coined the 
“Yamanaka Factors”, paved the way for a new era of translational and regenerative 
medicine, earning Takahashi and Yamanaka Nobel prize recognition.  
The mouse iPSCs produced via the cellular reprogramming technique were 
indistinguishable from mouse embryonic stem cells in proliferation, morphology, 
teratoma formation and gene expression. Takahashi and Yamanaka also established the 
iPSCs ability to form germline transmission competent, adult chimeras produced by the 
transplantation of iPSCs into blastocysts. Since the discovery of the induction of 
pluripotent stem cells from somatic cells, there has been abundant number of studies and 
research papers published with the task of refining the technique. Initial generation of 
iPSCs implemented the use of viral vectors, the method integrated both the vector 
backbone and transgenes into the genome permanently (Takahashi et al., 2014). 
Although this method was shown to successfully produce iPSCs, these vectors also 
produced insertional mutations which interfered with normal iPSC function whilst the 
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residual transgene expression was shown to influence differentiation into varying cell 
lineages and could even result in tumorigenesis (Drozd et al., 2015). In order to combat 
this, efforts have been made in order to develop vector integration-free mouse iPSCs, 
with resulting cells obtained through derivation of liver cells with adenoviral vectors and 
embryonic fibroblasts. Although seen as an adequate replacement, the low frequencies 
obtained show the limitations in practicality for this approach vis-à-vis human cells, which 
require enhanced exposure to reprogramming factors (Hu, 2014). 
 
 
 
 
 
 
 
 
 
Figure 2: Somatic cell reprogramming 
Figure 2: Figure above depicts the stages of reprogramming somatic cells to iPSCs through the ectopic 
expression of the transcription factors; Oct4, Sox2, C-Myc and Klf4. Initially the integration of these factors 
was achieved through lentiviral or retroviral vectors, however more recently progress has been made 
through the utility of plasmids and episomal adenovirus along with non-DNA beased techniques such as 
miRs and mRNAs. Once induced into the pluripotent state, iPSCs are able to differentiate into all three germ 
layers that can be utilised in disease modelling, cell therapy and drug discovery. (Menon et al., 2016) 
 
More recently, the development of inducible pluripotent stem cells derived from the 
single transfection of the episomal virus, oriP/EBNA1 (Epstein-Barr nuclear antigen-1) has 
become the forefront of somatic cell reprogramming to iPSCs (Drozd et al., 2015). The 
oriP/EBNA1 vectors are ideal for cellular reprogramming of human somatic cells, theses 
plasmids allow for the transfection whilst relinquishing the need for viral packaging, thus 
are able to be removed from cell types via cell culture in drug absent conditions. 
 
20 | P a g e  
 
oriP/EBNA1 vectors within mammalian cells possess a stable, extrachromosomal 
replication and thus requires only trans-acting EBNA1 gene along with a cis-acting oriP 
element. These oriP/EBNA1 vectors have a replication frequency of once per cycle and 
have been shown to establish stable episomes in ~1% of the initial transfected cells under 
drug selecting conditions. Conversely, the removal of these conditions have 
demonstrated the loss of these stable episomes at ~5% per cell generation due to defects 
in partitioning and plasmid synthesis. (Junying et al., 2009) 
1.3.1 Neural Stem Cells (NSCs) and their Differentiation 
The central nervous system (CNS), is generated from a small number of neural stem cells 
(NSCs) lining the neural tube, during development (Zhao and Moore, 2018). Studies in 
adult brains have demonstrated a reduction in NSCs in specific brain regions. Continued 
neurogenesis in hippocampus was confirmed in the 1990’s, which, at the time, 
contradicted the prevailing dogma that neurogenesis did not occur within a fully 
developed human brain, whilst hinting at the possibility of utilising these NSCs for neural 
repair in disease (Zhao and Moore, 2018).  
NSCs are multipotent stem cells with the capacity to self-renew and give rise to the three 
major cell types which make up the CNS in a defined sequence; firstly, neurons, followed 
by astrocytes and then oligodendrocytes (Han et al., 2017).  
Current research utilises hESCs and hiPSCs as cellular based platforms for differentiating 
into cell lines of interest. Research into neurodegenerative diseases has been hampered 
due to difficulties in obtaining neuronal cells and successfully culturing in vitro, however, 
the introduction of iPSC technology has revolutionised the field of research (D’Aiuto et al., 
2014). Various studies have demonstrated that iPSC-based models have the capacity to 
model selected aspects of neurological and neurodegenerative disorders (Zhao and 
Moore, 2018). Such platforms require cost effective, efficient and replicable protocols in 
order to generate uniform cultures of neurons in ample numbers for high throughput 
screening (D’Aiuto et al., 2014). Currently, neuronal differentiation techniques first derive 
NSCs/NPCs from hESCs or iPSCs. Many techniques currently initiate neural differentiation 
through the use of Noggin, a bone morphogenesis protein (BMP) inhibitor, a crucial 
neural-inducing factor in mammalian cells (Han et al., 2017). Different techniques are 
employed, however the most prevalent is the generation of embryoid bodies (EBs) 
followed by differentiation to neural rosettes (Tang, Yu and Cheng, 2017). These EBs are 
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3-dimensional, spherical aggregates that mirror a variety of key traits from early 
embryogenesis (D’Aiuto et al., 2014). When cultured in specific selective culture media 
and growth factors, these aggregates generated from human iPSC or ESCs will 
differentiate into neural rosettes efficiently, however, factors such as their initial size can 
have an impact on their differentiation outcome (D’Aiuto et al., 2014). Microwell arrays 
have been developed, these allow for a more efficient homogenous and uniform 
differentiation of EBs. The neural rosettes formed (representing a distinct class of NSCs), 
are isolated mechanically and transferred into low attachment plates where they form 
neurospheres (spherical cell aggregates), that can be propagated as 3-dimensional 
structures or expanded as a monolayer culture of NSCs/NPCs (D’Aiuto et al., 2014). 
Generally, monolayer cultures are favoured as neurospheres are not ideal for high-
throughput production of neurons due to technical difficulties in loading uniform 
numbers of spheres with identical size into multiple wells (D’Aiuto et al., 2014). Many 
terminal differentiation steps from NSCs to neurons involve the induction of a different 
selective media with other growth factors on adherent culture systems previously coated 
with attachment factors (AFs) such as poly-L-ornithine (Ge et al., 2016). Various studies 
have shown the advantages of using poly-L-ornithine opposed to other AFs, however, one 
study demonstrated that NSCs had a preferred neuronal differentiation via the ERK 
signalling pathway (Ge et al., 2015).  
 
1.4 Cellular Metabolism 
Metabolism in human stem cells is tightly regulated in order to maintain the cells ability 
to self-renew and maintain pluripotency, with evidence showing a metabolic shift during 
differentiation (Ito and Suda, 2014). Studies have shown that differing stem cells, 
including those of iPSCs and neural stem cells (NSCs), exist within a hypoxic niche. 
Evidence suggests that the low oxygen tensions formed through hypoxia aid in the 
maintenance of an undifferentiated state and influence cell-fate and proliferation (Simsek 
et al., 2010). Dormant human stem cells (HSCs) reside in a hypoxic niche located within 
the bone marrow cavity, indeed studies have shown that the oxygen saturation within the 
bone marrow is low with an oxygen tension of 10-30mm Hg (1.3-4.2%), obtained via the 
integration of two-photon intravital imaging (Ito and Suda, 2014). Due to stem cells 
existing in this hypoxic environment, a reliance on anaerobic glycolysis opposed to 
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mitochondrial oxidative phosphorylation (OXPHOS) has been observed for ATP 
production (Koopman et al., 2013). Metabolic analyses of HSCs have shown the metabolic 
profile of these stem cells differ significantly than those of committed progenitors. It was 
shown that HSCs possess increasing levels of fructose-1,6-bisphosphate accompanied 
with an increase in pyruvate kinase activity, indicative of active glycolysis (Lunt and 
Vander Heiden, 2011). Studies have further supported the notion of HSCs favouring 
glycolysis as it has been shown there is decrease in the level of phosphoenolpyruvate 
whilst also showing an increase in pyruvate production, the substrate and product, 
respectively, of the final step in glycolysis (Simsek et al., 2010)(Gu et al., 2016).  
Glycolysis is the process in which a molecule of glucose is metabolised to three-carbon 
pyruvate through ten steps. The glycolytic pathway enables the phosphorylation of 
glucose in order to produce glucose-6-phosphate, which is then converted to fructose-6-
phosohate which is subsequently phosphorylated in order to produce fructose-1,6-
biphosphate (Takubo et al., 2013). During this two-step process of phosphorylation, two 
molecules of ATP are consumed. Dihydroxyacetone phosphate and glyceraldehyde 3-
phospahte are produced through the degradation of fructose-1,6-biphosphate, with 
glyceraldehyde 3-phospahte is oxidised and further phosphorylated in order to form 1,3-
biphosphoglycerate via inorganic phosphate during the glycolytic payoff phase (Lunt and 
Vander Heiden, 2011). Subsequently, the latter is then converted to produce the 
molecule, 3-phosphoglycerate thus producing a molecule of ATP due to substrate-level 
phosphorylation. The consequent 3-phosphoglycerate is isomerised yielding 2-
phosphoglycerate which is dehydrated resulting in the formation of phosphoenolpyruvate 
(Lunt and Vander Heiden, 2011). As a result, the phosphoenolpyruvate is converted to 
pyruvate with the conversion producing another molecule of ATP. Four molecules of ATP 
are produced through two steps of substrate-level phosphorylation as two molecules of 
3-phosphoglycerate are converted to two molecules of pyruvate through oxidation (Gu et 
al., 2016). Per molecule of glucose oxidised, there is a net yield of molecules of ATP as 
two molecules are utilised during the glycolytic preparatory phase. Due to hypoxia, 
pyruvate is able to be reduced in order to from lactate in hypoxic conditions, alternatively 
it is able to be oxidised in order to yield acetyl-coenzyme A (Acetyl-CoA) when exposed to 
aerobic conditions and is also able to be completely oxidised to form CO2 through the 
induction of the citric acid cycle (Takubo et al., 2013) 
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Figure 3: The glycolytic pathway 
Figure 3. Figure depicts the glycolytic pathway along with its integration and association with other 
metabolic pathways (Takubo et al., 2013). 
 
Although iPSCs and NSCs maintain metabolic homeostasis through glycolysis, neurons 
require an increased amount of ATP for cellular respiration due to a lack of glycogen and 
high cellular demands, with energy requirements met via oxidative phosphorylation 
(OXPHOS) (Koopman et al., 2013). It has been demonstrated through a variety of studies 
that mitochondrial OXPHOS dysfunction leads to wide array of neurological disorders, 
especially observed in neurodegenerative diseases (Ivanov et al., 2014). Observations 
have shown the disappearance of HK2 and LDHA coupled with PKM2 splicing to form 
PKM1 initiates the metabolic shift from aerobic glycolysis to OXPHOS in neural 
differentiation of NPCs to neurons (Hüttemann et al., 2007). The disappearance of these 
markers has been shown to signal differentiation towards neurons, however constitutive 
expression of HK2 and LDHA results in neuron death, indicative of the importance of 
 
 
24 | P a g e  
 
inhibition of glycolysis in neural differentiation (Ito and Suda, 2014). Although it is widely 
regarded that neurons require OXPHOS for cell maintenance, the mechanisms by which 
the pathway is favoured is largely unknown. 
Mitochondrial oxidative phosphorylation (OXPHOS) is plays a crucial role in cellular 
energy metabolism and sustains organelle function. The OXPHOS system utilises the 
electron transport chain combined with cell respiration and ATP synthesis in order to 
generate the majority of cellular energy, whilst also being involved in free radical 
production and apoptosis (Ivanov et al., 2014). The electron transport, a key element of 
the OXPHOS system, comprises NADH-dehydrogenase (complex I), succinate 
dehydrogenase (complex II), ubiquinone bc1 complex (complex III) and cytochrome c (Cyt 
c) with cytochrome c oxidase (CcO- complex IV) (Hüttemann et al., 2007). Electrons 
transferred via the electron transport chain are mainly derived through NADH and are 
able to infiltrate the chain through complex I. Additionally, electrons are also able to be 
fed directly into the ubiquinone/ubiquinol pool via complex II. The electrons are able to 
transfer through the electron transport chain to oxygen, whilst the movement of protons 
across the inner membrane of the mitochondria generates the mitochondrial membrane 
potential. This proton gradient is used by ATP synthase (complex V), coupling the 
backflow of the protons which had previously been transported by the electron transport 
chain in order to produce ATP (Hüttemann et al., 2007).  
 
 
 
 
 
 
 
 
 
Figure 4: OXPHOS Pathway in mammalian cells 
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Figure 4. Figure depicts the regulation of OXPHOS within mammalian cells. Functionally, OXPHOS is tightly 
regulated via a hierarchy of regulatory mechanisms; tissue-specific isozymes are expressed by organs, 
signals from outside of the cell are mediated to mitochondria through signalling cascaded and allosteric 
regulation results in the alteration of energy production within the intermembrane space (Hüttemann et al., 
2007). 
 
1.5 Autophagy  
Over the past decade, investigation into macroautophagy (hereafter referred to as 
autophagy) and its biological mechanisms has been a staple in molecular biology due to 
its vital role in physiological and disease processes. Autophagy is an evolutionary 
conserved catabolic pathway, vital for its necessity in physiological processes, at the 
forefront is in which long-lived proteins and damaged organelles are delivered to 
lysosomes for degradation in order to maintain energy homeostasis (Johansen and 
Lamark, 2011). Autophagy arises when the sequestered proteins and organelles forming 
an autophagasome fuse with a lysosome in order to degrade the cargo. Autophagy 
proceeds in sequential steps in order to form mature autophagosomes; (i) de novo 
formation of a phagophore, a small membrane cistern eventually sealing itself into a 
double-membrane bound structure, (ii) elongation of this lipid-based membrane, before 
(iii) encapsulation of intracellular cargo to form a mature autophagosome (Thelen et al., 
2012). This autophagasome fuses itself with the endocytic system so that it may deliver 
its contents to lysosomes in order for degradation to occur. Once classed as a type of 
programmed cell death, autophagy is widely viewed as a basic cell survival mechanism, 
which has been found to be critical in the circumvention of nutrient stress and starvation, 
initially found in the study of yeast cells, of which the first genes relating to autophagy 
were discovered (Chen et al., 2014). Subsequently, various studies highlighting the 
importance of autophagy in mammalian cell counterparts have been carried out, 
displaying the importance of this catabolic pathway in cell maintenance and normal 
development.  
The group of hereditary neurodegenerative diseases, NCLs, are attributed to a loss or 
impairment of autophagy, with the autophagy-lysosome pathway enabling the 
degradation of damaged organelles, long-lived proteins and the clearance of intracellular 
pathogens and toxic protein aggregates (Ganley et al., 2011). Various studies have found 
that an impairment of these autophagic pathways results in the accumulation of 
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ubiquitin-positive aggregates within the cytoplasm, leading to neurodegeneration in NCL 
patients. (Katsuragi, Ichimura and Komatsu, 2015) 
The complete cellular pathway of autophagy occurs in sequential steps (figure 5); 
initiation, phagophore expansion, autophagasome maturation, fusion with the 
vacuole/lysosomes, cargo degradation in the lysosome and efflux (Thelen et al., 2012). 
The nature of the various steps makes it vital to assess autophagic activity at each step or 
to monitor flux. Currently in most mouse models, many of the ‘core’ ATG genes ae 
knocked out in order to observe and understand the physiological role of autophagy in 
mammals (Wang et al., 2013).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A 
D 
C 
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Figure 5: Autophagic Cellular pathways 
Figure 5: The cellular pathways during autophagy follow distinct, sequential steps: (A) vesicle nucleation 
(the formation of the isolation membrane/phagophore), (B) vesicle elongation (growth and closure), (C) 
fusion of the double-membraned autophagosome along with lysosomes in order to form an autolysosome 
and (D) finally the lysis of the autophagosome inner membrane leading to the breakdown of its contents 
within the autolysosome. Here are shown the complexes identified in mammalian cells, excluding Atg13 
and Atg17- found only in yeast cells. Autophagic inhibitors and activators are shown above in red and green, 
respectively (Levine and Kroemer, 2008). 
 
2.0 Aims 
The overall aim of the project is to utilise existing techniques from within the McKay lab 
as well as current literature, in order to successfully differentiate CLN7 patient and 
control induced pluripotent stem cells to neural progenitor cells and subsequently 
neurons. In order to achieve this, a stepwise protocol, allowing for the minimization of 
induction of a variety of exogenous growth factors, thus encouraging differentiation of 
neuroectoderm will be implemented. Through successful differentiation of CLN7 iPSCs 
and controls, analysis utilising techniques such as qPCR, western blot analysis and 
immunocytochemistry will be implemented in order to deduce any phenotypic 
differences between the two cell types. Targets relating to metabolism, inflammation, 
potency and autophagic flux will be interrogated in order for this deduction. Currently, 
very little information is given for CLN7, however, there has been extensive research 
directed towards neuronal ceroid lipofuscinosis in the last decade with each variant 
sharing an impairment in autophagy. Due to this common trait amongst the varying NCL 
variants, we hypothesize that there will be a decrease in autophagic flux in CLN7 cell 
types when compared to control counterparts, with an increase in lysosomal storage 
material expected. We also hypothesise a change in metabolic shift expected due to 
intrinsic links between regulation of cell homeostasis and metabolism. Although we 
expect to see differences, previous research within the McKay lab has shown that CLN7 
iPSCs display little to know difference in phenotype, this leads us to believe that any 
changes observed will occur as iPSCs differentiate towards neuronal progenitor cells and 
thus neural cells.  
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3.0 Materials and Methods 
3.1 Materials  
Table 3:  Cell culture reagents 
   
Reagent Company Catalogue Number 
DMEM Sigma D6546 
MEM Non-essential amino 
acids (NEAA) 
Life Technologies 1140050 
L-glutamine Sigma G7513 
Penicillin/Streptomycin 
(Pen/Strep) 
Sigma P0781 
Dulbecco’s Phosphate 
buffered saline 
Sigma D8662 
DMEM F12 Gibco, Life technologies 31331093 
Β-mercaptoethanol Life Technologies 31350-010 
Mitomycin C Sigma Aldrich M4287 
TrypLE express Gibco, Life Technologies 12605028 
bFGF R&D Systems 233-FB-025 
Laminin Millipore CC095 
Gelatin from porcine skin Sigma G1890 
Rock Inhibitor (Y-27632) Sigma Y0503-1mg 
Dimethyl sulfoxide Sigma BP231-100 
N2 supplement Life Technologies 17502048 
B27 supplement Life Technologies 12587010 
Heparin Sigma 12587010 
Matrigel BD Bioscience H3149 
MTeSRTM Stemcell Technologies 05851/05852 
Neurobasal media  Thermo Scientific 21103049 
Sodium Pyruvate Sigma Aldrich  P2256 
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Table 4: Materials 
Materials Company Catalogue Number 
RIPA buffer Thermo Scientific  89900 
Bradford Reagent BioRad 500-0006 
Acrylamide/bis-acrylamide 
30% 
Sigma A7802 
TEMED Sigma T9281 
Tween 20 Sigma 19379 
Pageruler Prestained protein 
ladder  
Thermo Scientific 26616 
Marvel Original dried 
skimmed milk 
Supermarket n/a 
Protease inhibitor cocktail Sigma Aldrich P8340 
Phosphate buffered saline 
tablets 
Sigma P4417 
Immobilon Western 
Chemiluminescent HRP 
substrate 
Merck WBKLS0500 
APS Sigma 215589-100G 
Blot absorbent filter paper  BioRad 1703932 
Methanol Fisher Scientific  10667032 
Glycine Sigma G8898-500G 
Tris base Fisher Scientific  BP152-1 
Sodium dodecyl sulphate  VWR International 27926.238 
RNeasy mini kit Qiagen 74104 
RQ1 RNase-free DNase kit Promega M6101 
dNTPs Promega PRU1240 
M-MLV reverse transcriptase Promega M1701 
RNasin plus inhibitor Promega N2611 
Random primers Promega  C1181 
KAPA SYBR FAST universal 2x 
qPCR master mix 
KAPA Biosystmes K4601 
GelRed nucleic acid stain VWR International 41003. 
Agarose Sigma A5093 
O’Generuler ladder mix Fisher Scientific  1188393 
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Isopropanol Sigma 190764 
4% Paraformaldehyde Sigma 15812 
Triton X-100 Sigma T8532 
Bovine Serum Albumin (BSA) Sigma  05479 
 
Table 5: Neural Induction Media (NIM) 
Component Volume 
DMEM/F12 1:1 48.5 mL 
NEAA 0.5 mL (1x) 
N2 0.5 mL (1x)  
bFGF 10 µL (20ng/mL) 
Heparin 50 µL (2µg/mL) 
Pen/Strep 0.5 mL (1x)  
Plasmocin 50 µL 
 
Table 6:  Neural Expansion Media (NEM) 
Component Volume  
DMEM/F12 (1:1) 48.5 mL 
NEAA 0.5 mL (1x) 
N2 0.5 mL (1x) 
B27 1 mL (1x) 
bFGF 10 µL (20ng/mL) 
Heparin 50 µL (2µg/mL) 
Pen/Strep 0.5 mL (1x) 
Plasmocin 50 µL 
 
Table 7: Neural Maturation Media (NM) 
Component Volume  
DMEM/F12 (1:1) 48.5 mL 
Horse Serum 0.5 mL (1%) 
B27 1 mL (1x) 
Pen/Strep 0.5 mL (1x) 
Plasmocin 50 µL 
 
Table 8: Complete DMEM 
Component Volume 
DMEM 435 mL 
FBS 50 mL 
L-Glutamine (200mM) 10 mL (4mM) 
Pen/Strep 0.5 mL (1x) 
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3.1 Cell Culture 
Induced pluripotent stem cells (CLN7 466, 474 as well as control) originally cultured on 
mouse embryonic fibroblasts (MEFs) in complete DMEM media (see table 7) until desired 
confluency. Following maturation of iPSCs, cells were transferred onto Matrigel covered 
plates and cultured in feeder free stem cell culture media, mTESR, supplemented with 
Plasmocin antibiotics. The commercially available human embryonic stem cell (hESCs) 
line, Shef3, was purchased from the UK stem cell bank. These cells were cultured under 
feeder free conditions in mTESR, supplemented with Plasmocin antibiotics, incubated at 
37oC and 5% CO2. CLN7 HDFs and nHDFs, as well as HEK293 cells were cultured in 
complete DMEM prior to reprograming in 6-well plate format, supplemented with 
Plasmocin antibitoics. All cells were incubated at 37oC and 5% CO2 
 
3.2. Neural Differentiation 
72 hours prior to neural differentiation, neural induction media containing Poly Vinyl 
Alcohol (PVA) was prepared. PVA at a concentration of 4mg/mL (i.e. 200mg in 50mL) was 
added to DMEM/F12 and shaken vigorously for one hour followed by placing media on a 
roller for 72 hours at 4oC in order to completely dissolve PVA. The media was then filtered 
through a 0.22µm PES syringe driven filter in order to sterilise. Subsequent media was 
supplemented with factors listed in table 4. 
Feeder free iPSCs were enzymatically disrupted using TrypLE in order to obtain a single 
cell suspension, cell containing suspension was centrifuged at 1080g (1200rpm) for 5 
minutes. Pellet formed was resuspended in NIM, in a 96 V bottom well plate at a seeding 
density of 7,500 cels/well (100µL media containing cells/well). 24 hours post seeding, 
neuroepithelial cell clusters formed in the suspension. Media was replaced every day for 
the following five days. On day 6, aggregates were re-seeded onto laminin coated dishes 
(20µg/mL) to allow for the formation of neural rosettes (2-3 days). Once rosettes had 
formed, rosette clusters were picked using a 21-gauge sterile needle. Cell clusters were 
centrifuged at 200g for 3 minutes and resuspended in Neural Expansion Media (see table 
5). Subsequent media can be cultured on low attachment plates in order to promote the 
proliferation of Neural Stem Cells (NSCs), however, during the project, Neural progenitor 
cells were cultured as a monolayer on laminin coated dishes (20µg/mL). Following 
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protracted culture, the NPCs were enzymatically disrupted using TrypLE and centrifuged 
at 800g for 8 minutes, pellet was then resuspended in Neural Maturation Media (see 
table 6) and reseeded onto laminin coated dishes of a 6 well plate at a seeding density of 
50,000 cells/well. Half media changes were performed every 3 days in order to prevent 
cell overexposure to surrounding air. Cells were continually cultured until visual formation 
of axons of the neuronal cells.  
3.3 Bradford assay: 
Cell types of interest that were utilised for western blot analysis were initially lysed 
through the use of RIPA buffer augmented with 1µL: 100µL of protease inhibitor cocktail. 
The subsequent lysates were then stored in the -80OC freezer until required. 
Prior to the implementation of Western Blot analysis, total protein was quantified 
utilising a Bradford assay, the preferred colorimetric assay for quantifying total protein 
concentration. Initially, Bradford reagent was diluted at a 1:5 ratio (v/v) with deionised 
H2O. 195µL of the diluted Bradford reagent was then added in triplicate to wells of a 
nucleon delta surface, transparent 96-well plate. 5µL protein standards were then added 
to wells containing diluted Bradford reagent in increasing concentrations from 0.5µg - 
8µg/µL. Prior to the addition of experimental lysates to wells containing Bradford 
reagent, the lysates were diluted 1:10 in deionised water in order to minimise the effects 
of RIPA buffer on Bradford reagent when estimating protein quantification. The 
consequent standard and sample containing, 96-well plate was then analysed by the 
Synergy HT microplate spectrophotometer at an absorbance of 630nm. 
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Figure 6: Typical Bradford Assay Set-up 
Figure 6: Typical representation of a Bradford assay plate prior to spectrophotometric analysis. Columns A-F 
(rows 1-3) represent the triplicate standards of increasing protein concentration from 0µg/5µL (A) - 8µg/5µL 
(F). Column A (rows 5-7) represent example of loaded lysate samples for quantification determination. A 
standard curve is then produced via spectrophotometer analysis of standards, from which the protein 
lysate can be quantified.  
 
 
3.4 Polyacrylamide Gel Electrophoresis   
Table 9: 10% Acrylamide Gel 
Separation gel: Stacking gel: 
3.33mL (3:1) acrylamide : ddH2O 0.67mL 3:1 acrylamide:ddH2O 
4.17mL ddH2O 2.3mL ddH2O 
2.5mL Solution A 1mL solution B 
10µL Temed 5µL Temed 
50µL APS 30µL APS 
 
Table 10: 15% Acrylamide Gel 
 
Table 11: Solution A- pH adjusted to 8.8 
Component Concentration 
Tris-HCL 1.5M 
SDS 0.4% 
 
 
 
Separation gel  Stacking Gel 
5 mL (3:1) acrylamide : ddH20 0.67mL 3:1 acrylamide:ddH2O 
2.4 mL ddH20  2.3mL ddH2O 
2.5 mL Solution A 1mL solution B 
10 µL Temed 5µL Temed 
100 µL APS 30µL APS 
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Table 12: Solution B- pH adjusted to 6.8 
Component Concentration 
Tris-HCL 0.5M 
SDS 0.4% 
 
SDS-PAGE  gels can be imported pre-cast; however, in the McKay Lab we opted to 
produce our own gels in order to alter the percentage of the acrylamide depending on 
the size of the target protein. Prior to manufacturing the gels, the glass plates (1.0mm 
used throughout) are placed in the clamp and tested for leakages using ddH2O or 70% 
ethanol. During the project various percentage gels were produced in relation to the size 
of the protein of interest. For the production of a 10% gel, the following was carried out 
for separation gel; 1mL ddH2O added to 3mL 30% acrylamide, 3.33mL of the mixture was 
transferred into a new falcon tube (A), leaving 0.67mL in remaining tube (B). Followed by 
the addition of 4.17mL ddH2O added to tube A. A volume of 2.5mL of solution A (see table 
9) is then added to tube A. Immediately before pouring mixture into 1.0mm plates, 50µL 
of APS and 10µL TEMED is added to tube A causing mixture to polymerise and solidify 
after approximately 20 minutes. When producing the stacking gel, the following was 
performed; 2.3mL ddH2O was added to tube B followed by the addition of 1mL of solution 
B (see table 7). Immediately before pouring mixture into 1.0mm plates, 30µL APS and 5µL 
TEMED was added to cause polymerisation of gel. Formula for the separation gel of 
differing percentage gels was altered accordingly (refer to tables 9 and 10). Gels produced 
are able to be stored for ~1 week in PBST buffer stored at 4oC.  
3.5 Western Blot Analysis 
Table 13: 10X Running Buffer 
Component Concentration 
Tris base 250mM 
Glycine 1.9M 
SDS 1% 
 
*Components are dissolved in 1 litre of ddH2O 
*This is then diluted 1:10 in ddH2O for final use  
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Table 14: 1x Blotting Buffer 
Component Concentration 
Tris base 25mM 
Glycine 190mM 
Methanol 20% 
 
*Components are dissolved in 1 litre of ddH2O 
Once total protein quantity of cells of interest was established, immunoblotting vis-a-vis 
Western blot was implemented. Throughout the project a protein quantity of 20µg was 
loaded per well as previous work found this to be the optimal quantity. Laemmli buffer 
was added to the protein sample at a dilution of 1:5 and incubated at 95OC for 5 minutes, 
this allows for the degradation of disulphide bridges in the proteins, allowing for the 
adoption of random coil conformation thus allowing for better separation along the SDS-
PAGE gels. Whilst this is occurring the gels were loaded into the tank, which was filled 
with 1x Running Buffer (see table 9). Once the proteins had been incubated for 5 minutes, 
they were loaded into the wells of the SDS-PAGE gel alongside the PageRuler Prestained 
protein ladder; image below demonstrates the SDS-PAGE band profile of the PageRuler 
Prestained protein ladder: 
 
 
 
 
 
 
 
 
 
Figure 7: PageRuler Prestained Protein Ladder Used throughout Western Blot Analysis 
 
36 | P a g e  
 
Figure 7: representation of the SDS-PAGE band profile of the Page Ruler Prestained protein ladder used 
throughout western blot analysis. 
The gels were then run at 90V until the proteins had passed through the stacking gel and 
had entered the separation gel, following this the voltage was increased to 120V and was 
run for a further 1.5-2 hours. Following the completion of the run, four pieces of blotting 
paper, as well as a nitrocellulose membrane were soaked in 1x blotting buffer (see table 
10). The gel cast was transferred onto a nitrocellulose membrane with two pieces of 
blotting paper above and below the nitrocellulose and was run on the blotter for one 
hour at 15V. Following the transfer, the membrane was blocked for a minimum of one 
hour using block solutions relative to the target antibody, throughout the project milk 
block (5% w/v non-fat milk powder in PBS + 0.01% Tween 20) and BSA block (5% w/v 
bovine serum albumin in PBS + 0.01% Tween 20). The block was then removed and 
incubated with primary antibody of interest, which was dilute in corresponding block at 
the dilution recommended by the data sheet from the company from which they were 
bought. The primary antibody was incubated overnight at 4OC. The primary antibody was 
then removed and the membrane was washed with PBS + 0.01% Tween 20 three times 
for ten minutes per wash. Following this, the secondary antibody was then diluted in 
either milk block or BSA block at appropriate dilution, the membrane was then incubated 
in the secondary containing block at room temperature for one hour. The membrane was 
then washed using PBS + 0.01% Tween 20 three times for ten minutes per wash. The 
membrane was then incubated with ECL for one minute. All images produced were 
visualised on the Biorad Chemidoc touch gel dock transilluminator using western gel 
settings. 
 
 
 
 
 
 
 
37 | P a g e  
 
Table 15: Antibodies Utilised in Western Blot Analysis 
Antibody Dilution Secondary Company Catalogue 
Number 
P62 1:2000 Mouse Abcam Ab86416 
P70 1:1000 Rabbit Cell 
Signalling 
2708S 
p-p70 1:1000 Rabbit Cell 
Signalling 
9205S 
-actin 1:10,000 Mouse Sigma 
Aldrich 
A2228 
 
3.6 RNA Extraction 
Prior to RT-PCR, RNA was extracted from desired cells once they reached appropriate 
confluency, with no more than 1 x 107 cells harvested. The cells were enzymatically 
disrupted using TrypLE express and washed with PBS; the cells were centrifuged at a 
speed of 1080g for 5 minutes until a pellet formed. The supernatant was then removed 
and was re-suspended in 350 µL of Buffer RLT (acts as a lysis buffer for RNA isolation), the 
sample was then immediately taken to the -80 freezer where it was left overnight. 
Following the lysis of the cells, the samples were thawed and homogenised via pipetting 
through 25G needle and syringe. Following this, the RNA was isolated from the sample 
using the RNeasy mini kit and subsequent protocol provided by Qiagen. Following this, 
one volume (350µL) of 70% ethanol is added to the lysate and is well pipetted in order for 
the ethanol to sufficiently mix with the lysate. Up to 700µL of the sample, including any 
precipitate, was then transferred to an RNeasy Mini spin column in a 2mL collection tube 
(both supplied by Qiagen) and was centrifuged for 15 seconds at ≥8000g, the subsequent 
flow through was discarded. Subsequently the mixture then undergoes DNase digestion 
in order to remove any genomic contaminant from the sample. To begin, 350µL Buffer 
RW1 was added to the RNeasy column and centrifuged at ≥8000g for 15 seconds, with 
the flow through discarded. From here, 10µL of DNase I stock solution was added to 70µL 
of Buffer RDD (63µl RNase free ddH2O + 7µL 10x DNase buffer) and mixed by gently 
inverting the tube and briefly centrifuging. The DNase I incubation mix (80µL) was added 
directly to the RNeasy column membrane and was incubated at room temperature for 15 
minutes. Following the DNase digest, 350µL of Buffer RW1 was added to the RNeasy 
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column and was then centrifuged at ≥8000g for 15 seconds with the flow through being 
discarded. Next, 500µL of Buffer RPE was added onto the column and centrifuged at 
≥8000g for 15 seconds, the flow through was then discarded. Again, 500µL of Buffer RPE 
was added directly onto the mini spin column; however, it was centrifuged for 2 minutes 
at ≥8000g. The flow through was once again discarded and the spin column containing no 
other buffer was centrifuged at ≥8000g for 1 minute in order to dry the membrane. Once 
the following step had occurred, the RNeasy spin column was transferred into a new 
1.5mL collection tube (supplied by Qiagen) and 30µL of RNase free water was added onto 
the spin column and left to stand for 5 minutes before it was centrifuged for 1 minute at 
≥8000g. The remaining 30µL sample in the 1.5mL collection tube contained the total RNA 
content of the desired cells. Once the RNA had been successfully isolated, the amount of 
RNA in the sample was quantified by loading 1µL of the sample onto the NanoDrop 
Microvolume Spectrophotometer and Fluorometer.  
 
3.7 Reverse Transcrption 
Once RNA extraction had been successfully completed, cDNA was produced in order to 
perform Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR). One microgram of 
the RNA product was suspended in RNase free water up to 12.4µL, 1µL of random 
primers was then added and the complete mixture was incubated at 70oC for five 
minutes. Whilst the sample incubated, the following was made up per reaction: 
 5µL of M-MLV 5x reaction buffer 
 5µL of dNTPs – the monomeric substrates for the polymerization reaction, the 
DNA polymerase covalently link the free –OH group on the 3’ carbon of a growing 
chain of nucleotides to the α-phosphate on the 5’carbon of the next dNTP. 
 0.6µL RNasin- a ribonuclease inhibitor.  
 1µL M-MLV RT- a recombinant DNA polymerase that synthesizes a complementary 
DNA strand from single stranded RNA.  
Once the previously stated components were added to the mixture post 70oC incubation, 
the subsequent mixture was incubated at 37oC for one hour. Once the previous steps 
have been completed the mixture was incubated at 95oC for five minutes, following this 
RT-PCR was carried out, alternatively the mixture could be frozen in order to stop the 
reaction and thus RT-PCR can be conducted at a later date.  
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3.8 Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR) 
Following the successful generation of cDNA from RNA, RT-PCR was carried out in order 
to qualitatively demonstrate the expression of various endogenous genes (see table 12) in 
two different CLN7 iPSC patient lines and in controls as well as in CLN7 474 and Control 
NPCs produced through neural differentiation. Per reaction, the following solution was 
made:  
 
Table 16: Components and their corresponding volumes during RT-PCR reactions. 
Component  Volume  
5x Q5 Reaction Buffer 5µL 
10mM dNTPs 0.5µL 
10mM Primers (forward + reverse) 2.5µL 
Q5 DNA polymerase 0.25µL 
DNase/RNase free ddH2O 15.75µL 
cDNA 1µL 
 
The samples were then taken to the Agilent sure cycler 8800 thermocycler in order to 
perform the polymerase chain reaction, during the project the following cycling 
parameters were carried out: 
o 98oC x 5 minutes 
o 98oC x 30 seconds  
o 55oC x 30 seconds     x28 cycles 
o 72oC x 60 seconds  
o 72oC x 5 minutes 
The subsequent PCR products were ran along a 1-2% agarose gel supplemented with 
GelRed nucleic acid gel stain. All images produced were visualised on the Biorad 
Chemidoc touch gel dock transilluminator using GelRed nucleic acids settings.  
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Figure 8: O'generuler 1kb ladder used in RT-PCR analysis 
For primer information see appendix.  
3.9 Quantitative Polymerase Chain Reaction (qPCR) 
Following RNA extraction and in turn cDNA production, subsequent cDNA was diluted 1 in 
two in DNase/RNase free ddH2O. The following master mix was produced per reaction:  
o 5µL SYBR green 
o 3.6µL DNase/RNase free water  
o 0.4µL Primer (forward and reverse) 
o 1 µL cDNA 
9µL of master mix (excluding cDNA) was added in triplicate into a semi-skirted 96-well 
plate with the addition of 1µL of cDNA following. Following the addition of cDNA samples 
to subsequent master mix, the 96-well plate was covered using a plastic PCR film supplied 
from Thermofisher in order to prevent evaporation of samples. The plate was taken to 
the AB Step One Plus Real Time Thermocycler and was ran using standard SYBR settings 
including melt curves with 40 cycles. The data produced from the reaction was then 
exported into an Excel file, from which data analysis was undertaken in order to calculate 
relative expression with statistical analysis implementing the use of an independent T-
Test.  
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3.10 Immunofluorescent Cell Staining  
Cultured cells of interest had media removed before being washed with phosphate 
buffered saline (PBS) five times, however cells with surface adhesion issues were washed 
three times in order to compensate for their low adhesion. Cells were then fixed in 
paraformaldehyde diluted in PBS to a final concentration of 4% for 15 minutes. The fixed 
cells were then washed three or five times depending on the cell type, before the 
permeabilization step in which the cells are immersed in PBS containing 0.3% Triton-X100 
for ten minutes at room temperature. The cells were then washed again 3-5 times 
depending on cell type, before being blocked in PBS containing 2% bovine serum albumin 
(BSA) and 0.1% Tween 20 for a minimum of 30 minutes. The block was then removed, and 
the primary antibody was diluted at the appropriate dilution factor (see table 17 for 
dilution factor details) in the BSA and Tween 20 containing PBS block, the cells were then 
immersed in the suspension and left overnight at 4OC. The block containing the primary 
antibody was then removed and washed a further 3-5 times before the secondary 
antibody (see table 17 for details) was diluted in the PBS containing BSA and Tween 20 
block. The dilution factor of the secondary antibodies was dependent on the company 
from which they were purchased; Northern lights from R&D systems had a dilution factor 
of 1:400, whereas Alexa fluor from Invitrogen was 1:500. The cells were incubated in the 
block containing secondary antibody for one hour at room temperature in the dark due to 
the photosensitivity of the secondary antibodies. The block containing secondary 
antibody was removed before a final wash with PBS 3-5 times, the cells were then 
immersed in PBS and taken for viewing. All images produced for immunofluorescent 
staining were captured using the Leica CTR 600 live cell-imaging microscope.  
 
Table 17: Primary ICC Antibodies 
Antibody Species Dilution Company Catalogue 
Number 
Oct4 Goat 1:200 Abcam Ab27985 
Sox2 Goat 1:100 R&D Systems AF2018 
Tra-1-81 Mouse 1:200 R&D Systems MAB8495 
Lamp1 Rabbit 1:200 Abcam AB24170 
-III-tubulin Mouse 1:200 Abcam Ab7751 
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Table 18: Secondary ICC Antibodies 
Antibody Dilution Absorption 
(nm) 
Emission 
(nm) 
Company Catalogue 
number 
Donkey anti-
Goat IgG, 
Alexa Fluor 
568 
1:500 578 600 Thermo 
Fisher 
A11057 
Goat anti-
Mouse IgG, 
Alexa Fluor 
488 (Green) 
1:500 495 518 Thermo 
Fisher 
A10684 
Goat anti-
Mouse IgG, 
Alexa Fluor 
568 (Red) 
1:500 579 601 Thermo 
Fisher 
A11004 
Goat anti-
Rabbit IgG, 
Alexa Fluor 
488 
1:500 495 519 Abcam Ab150077 
DAPI 1:1000 348 453 Thermo 
Fisher 
D1306 
Mitotracker 
Red 
(Organelle 
Stain) 
!mM 
Solution 
581 644 Thermo 
Fisher 
M22425 
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3.11 Statistical Analysis 
Statistical analysis on qPCR data collected from iPSC and HDF analysis was performed 
using the one-way analysis of variance (ANOVA) with posy-hoc, Tukey analysis. Whereas 
analysis comparing data sets between patient NPCs and healthy controls was performed 
using Independent Samples t-tests. All data is expressed as the standard error of mean 
values (SEM) of experiments with an n=3, performed in triplicate. Values of p < 0.05 was 
considered statistically significant. All statistical analyses were performed using the 
software SPSS (Version 22.0, 2013, IBM Corp., Armonk, NY, USA; SPSS Inc,. Chicago, IL, 
USA).  
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4.0 Results 
The use of induced pluripotent stem cells has become an ever more prevalent and 
effective tool in disease modelling in vitro and for the generation of therapies. Indeed, 
previous studies have demonstrated the generation of various cell line via iPSCs through 
various differentiation protocols. In this study I sought to validate iPSCs available within 
the McKay lab from CLN7 patients, with the intention of performing neural 
differentiation in order to characterize the phenotypic changes occurring throughout 
neural differentiation.  
4.1 iPSC Production 
Induced pluripotent stem cell (iPSCs) lines for CLN7 patient cells and 
controls were provided by the McKay lab throughout the project, which 
were produced through somatic cell reprogramming. Firstly, HDFs of both 
patient and control cell lines underwent nucleofection through the use of 
the Amaxa Nucleofector 2b, thus supplying cells with episomal plasmid-
based reprogramming factors; SOX2, OCT4, KLF4, I-Myc and shp53, 
necessary for induction of pluripotency. Furthermore, in order to improve 
efficiency, additional EBNA1 expression plasmid was added. The schematic 
below depicts the McKay lab protocol for iPSC production via somatic cell 
reprogramming.  
  
Figure 9: Initiation and Production of iPSCs 
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Figure 9: Figure depicts the initiation and production of induced pluripotent stem cells from fibroblasts at 
each stage. Prior to initiation of stepwise protocol of iPSC production, HDFs first undergo nucleofection.  
 
4.2 CLN7 and Control iPSCs Display Pluripotent Characteristics 
Following somatic cell reprogramming, subsequent induced pluripotent stem cells were validated 
using reverse transcriptase PCR (RT-PCR) in order to qualitatively assess the cells pluripotency 
targeting the gene expression of Oct4, Lin28 and Nanog. Following successful assessment through 
RT-PCR, qPCR analysis was implemented in order to quantitatively assess pluripotency markers 
Lin28A and SOX2. Finally, immunocytochemistry was performed in order to definitively display 
CLN7 and controls pluripotency characteristics by staining for; Oct4, SOX2 and Tra-1-81.  
The targets; Oct4, Lin28 and Nanog, known to be expressed in pluripotent stem cells, were 
assessed. The transcription factor, Oct4, encoded by the Pou5f1 gene, belongs to the DNA 
binding-protein family POU (Pit, Oct, Unc) (Zeineddine et al., 2014). This family is known to be 
involved in the regulation of target genes via binding of the octamer motif, ATGCAAAT within 
their enhancer or promoter regions. Various studies have shown the importance of Oct4 in the 
maintenance of pluripotency, with a knockdown of Oct4 in mouse embryonic stem cells shown to 
result in the upregulation of endoderm associated genes such as α-fetoprotein and Gata6 as well 
as an upregulation of trophoblast differentiation such as Cdx2 (Zeineddine et al., 2014). 
Additionally, Oct4 acts as a repressor of the expression of human ES cell placental marker, hCG 
(human chorionic gonadotropin). In addition to this, the three transcription factors; Oct4, SOX2 
and Nanog, have been shown to co-operate in order to maintain pluripotency and self-renewal. 
Indeed, these transcription factors bind to the promoter of their own genes allow for their 
activation. In accordance with this, the transcription genes involved in ESC self-renewal; Dppa4, 
Tdgf1, Oct4, Nanog and Lefty2, are all positively regulated by Oct4, SOX2 and Nanog leading to 
the preferential expression in ESCs (Zeineddine et al., 2014) (Zhang, 2014). The central role these 
transcription factors play in pluripotency maintenance makes them a specific target of interest in 
order to validate CLN7 and control iPSCs. Furthermore, monitoring the expression of these 
transcription factors, the expression of epitopes recognized via the monoclonal antibody, Tra-1-81 
has been used frequently in the assessment of pluripotency status of ESCs and iPSCs (Natunen et 
al., 2011). Although it has been proven that epitopes that are recognized by Tra-1-81, are 
carbohydrates, the molecular identity of these epitopes is still a mystery (Natunen et al., 2011). 
Moreover, even though the exact molecular identity of this epitope is yet to be elucidated, it has 
been shown that Tra-1-81 recognizes the minimal epitope; Galβ1-3GlcNAcβ1-3Galβ1-4GlcNAc, 
present within human embryonic stem cells as part of the mucin-type-O-glycan structure. This 
demonstrates the validity of assessing the expression of Tra-1-81, however as the marker is 
recognized by cell surface antigens on pluripotent stem cells, the marker is only able to be 
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assessed through immunocytochemistry (Natunen et al., 2011). As well as these pluripotent 
markers, the RNA binding protein, LIN28A was assessed due to its function in maintaining cell 
pluripotency. LIN28A and LIN28B loci have been shown facilitate the conversion from naïve cells 
to pluripotent in murine cells whilst their importance in maximal reprogramming efficiency has 
been previously stated. In human fibroblasts, LIN28B is activated early within reprogramming, 
whilst LIN28A is activated in the latter stages of reprogramming in transition to induced 
pluripotent stem cells (Zhang et al., 2016).   
Throughout validation using RT-PCR and qPCR analysis of pluripotency, neural specific and 
metabolic markers, CLN7 iPSCs and control iPSCs, Shef3 ESCs and human embryonic kidney 293 
cells (HEK293) were also exposed to targets used. Shef3 cells were used in order to establish a 
positive control from which our iPSCs could be compared against, whilst HEK293s were used 
primarily as a negative control. HEK293 cells are one of the most widely used cell type in biological 
research. Despite this extensive use in research, the phenotype and karyotype still remain poorly 
understood (Stepanenko and Dmitrenko, 2015).  
4.2.1 RT-PCR Analysis of iPSCs Demonstrate Pluripotent Properties 
Initially, RT-PCR was performed in order to qualitatively assess the production of these 
pluripotent stem cell lineages. Once cells had reached the desired confluency (0.96-1.1 x 
106 cells or 80-90% confluency of one well of a 6-well plate), they were dissociated using 
TrypLE express, cells were then lysed using Buffer RLT prior to RNA extraction and 
purification. Throughout the validation of the iPSCs, two CLN7 cell lines were used via the 
reprogramming of somatic cells from two different NCL patients provided to the McKay 
lab through external collaborators denoted at CLN7 466 and CLN7 474. Figure 9 (below) 
demonstrates the expression of pluripotent markers; OCT4, LIN28 and Nanog in CLN7 
466, 474 iPSC in comparison to control iPSC as well as HEK293 and Shef3 cells. The results 
demonstrate the expression of pluripotency markers via RT-PCR analysis and gel 
electrophoresis, comparable to control counterpart, indicative of successful 
reprogramming to induced pluripotent state.  
 
 
 
 
 
47 | P a g e  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10: RT-Analysis of Pluripotency Markers in iPSCs 
Figure 10. Figure depicts RT-PCR products separated by agarose gel 
electrophoresis (2%) supplemented with GelRed at 15V for 1 hour for qualitative 
analysis of Oct4, Lin28 and Nanog pluripotency markers, respectively. PCR 
products from two CLN7 lines as well as control were compared against that of 
control iPSCs and embryonic stem cells (Shef3) and HEK293 cells and No reverse 
transcriptase negative control (No RT).  
 
 
 
 
 
 
 
 
 
CLN7 (466) iPSC CLN7 (474) iPSC Control iPSC 
HEK 293 Shef3 
No RT 
116 bp 
62 bp 
400 bp OCT4 
LIN28 
Nanog 
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4.2.2 Confirmation of Pluripotent Properties of CLN7 iPSCs Via Immunocytochemistry 
Following RT-PCR analysis, CLN7 474 iPSC and control iPSCs were immunostained for the 
potency markers; SOX2, OCT4 and Tra-1-81 in order to verify our RT analysis. Pluripotent 
stem cells from different stages post reprogramming were fixed and stained to assess 
any differences in maintaining pluripotency. CLN7 474 and controls cultured on MEFs 
were stained for the stated potency factors as well as feeder free iPSCs of the same cell 
lines, this was to ensure CLN7 iPSCs were able to maintain in an undifferentiated state 
comparable to controls. All cells were imaged using the Leica CTR 6000 Live Cell imaging 
microscope. Figure 11 shows positive staining results of pluripotency markers; SOX2, Tra-
1-81 and OCT4 in CLN7 iPSC compared against controls on MEFs. Images show 
immunocytochemistry results of CLN7 iPSCs comparable to that of controls, further 
indicating pluripotent properties displayed in RT-PCR results in figure 10. Furthermore, as 
iPSCs continued to develop towards feeder free, CLN7 and controls were stained for 
previously stated pluripotency markers to confirm retained pluripotency. Results display 
positive immunocytochemistry staining for SOX2, Tra-1-81 and OCT4 in the CLN7 474 
iPSCs and control counterparts. 
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Figure 11: Immunostaining of iPSCs on MEFs 
Figure 11: ICC of Pluripotency Markers in CLN7 iPSCs  
Figure 11. Images depict immunocytochemistry images CLN7 474 and Control iPSCs probed for pluripotency 
markers SOX2, Tra 1-81 and OCT4. Images (A) display CLN7 474 iPSC on MEFs phase and emission image of 
SOX2 pluripotency marker at 600nm. (B) Displays control iPSC on MEFs phase and emission image of SOX2 
pluripotency marker at 600nm. (C) images demonstrate CLN7 474 iPSC on MEFs phase and emission image 
of Tra-1-81 at 518nm. (D) images demonstrate Control iPSC on MEFs phase and emission image of Tra-1-81 
at 518nm. (E) Depiction of CLN7 474 iPSC on MEFs phase and emission images probed for pluripotency 
marker, OCT4 at 600nm. (F) Images show control iPSC on MEFs, phase and emission images probed for 
pluripotency marker, OCT4 at 600nm. All images shown at x20 magnification, with 100µm scale bar. 
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Figure 12: Immunostaining of Feeder Free iPSCs 
Figure 12: ICC of Pluripotency Markers in Feeder Free CLN7 iPSCs 
Fgure 12.  Images depict immunocytochemistry images CLN7 474 and Control iPSCs probed for 
pluripotency markers SOX2, Tra-1-81 and OCT4. Images (A) display feeder free CLN7 474 iPSC phase and 
emission image of SOX2 pluripotency marker at 600nm. (B) Displays control feeder iPSC phase and emission 
image of SOX2 pluripotency marker at 600nm. (C) images demonstrate feeder CLN7 474 iPSC phase and 
emission image of Tra-1-81 at 518nm. (D) images demonstrate feeder free Control iPSC phase and emission 
image of Tra-1-81 at 518nm. (E) Depiction of feeder free CLN7 474 iPSC phase and emission images probed 
for pluripotency marker, OCT4 at 600nm. (F) Images show feeder free control iPSC, phase and emission 
images probed for pluripotency marker, OCT4 at 600nm. All images shown at x20 magnification, with 
100µm scale bar. 
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4.3 Analysis of CLN7 and Control iPSCs Show Negligible Differences in 
Metabolism 
Following confirmation of successful generation of patient and control induced 
pluripotent stem cell lines, a variety of target genes were chosen in order to deduce any 
differences in metabolic profile of CLN7 iPSCs as well as subsequent differentiated NPCs 
(4.5) compared to that of controls. It was imperative to deduce the metabolic profile of 
CLN7 iPSCs in order to ascertain key changes that occur during differentiation and to 
confirm our hypothesis of a shift from oxidative phosphorylation of iPSCs to glycolysis in 
NPCs and more mature neuronal cells. 
Metabolic markers; NFB1, HO-1, PKM2, LDHA, HO-1, and UCP2 were 
investigated in order to deduce any metabolic shifts.  
Figure 13 (below) demonstrates the relative expression of various markers 
related to inflammation and metabolism in CLN7 iPSCs compared to 
control iPSCs as well as Shef3 embryonic stem cells and HEK293 cells. The 
purpose is to ascertain key differences in metabolic traits of CLN7 and 
controls in the early stages of differentiation, in order to discern any 
differences as differentiation progresses. Our results show that there was 
no statistical significance between the relative expression of the 
inflammatory marker NFB, in CLN7 iPSCs when compared to controls. 
There was also no statistical difference between the two iPSC lines and 
Shef3. The oxidative stress marker, HO-1, also demonstrated no statistical 
significance between the relative expression of CLN7 iPSCs and control 
iPSCs. However, it was found that both the iPSC lines showed a statistical 
difference in expression when compared to Shef3 cells, with an decrease in 
relative expression of 17-fold in Shef3 compared to control iPSC and 16.6-
fold decrease in relative expression when compared to CLN7 iPSCs.  CLN7 
iPSCs demonstrated a significant increase in expression of glycolytic 
enzyme, PKM2 compared to both control iPSCs and Shef3 with a 4.3-fold 
and 5.4-fold increase in relative expression, respectively. No statistically 
significant difference was found between the relative expression of LDHA 
in CLN7 and control iPSCs, however, Shef3 displayed a 5-fold increase in 
relative expression compared to CLN7 iPSCs, determined to be statistically 
significant. The expression of UCP2 was significantly decreased in both 
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CLN7 iPSCs and Shef3 cells when compared to control iPSCs, with a 
decrease in relative expression of 14.9-fold and 20-fold respectively. There 
was no statistical difference in the relative expression of UCP2 in CLN7 
iPSCs and Shef3 cells. 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13: Metabolic Changes in CLN7 iPSCs Compared to Controls 
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Figure 13: Metabolic qPCR targets of iPSCs 
Figure13: Differential expression of (A) NFB, (B) HO-1, (C) PKM2, (D) LDHA, (E) UCP2 
(n=3, three technical repeats) between CLN7 iPSCs against healthy iPSC as well as SHEF3 
positive ESC controls and HEK293s. Subsequently, single factor ANOVAs were performed 
with post-hoc Tukey analysis performed in order to determine statistical significance 
between groups. Statistical differences were as followed; (A) No statistical differences 
between CLN7 iPSC and Control iPSCs, both iPSC types displayed no statistical difference 
to SHEF3 cells. A value of p=0.034 between Shef3 and HEK293s displaying significance. (B) 
No statistical differences between CLN7 iPSC and Control iPSCs were calculates. A value of 
p=0.026 was calculated between control iPSCs and SHEF3, whilst CLN7 iPSCs also 
displayed significant differences with a p=0.021 calculated. Shef3 cells and HEK293s share 
a strong significance calculated at p=0.007. (C) Control iPSC displayed significant 
differences to CLN7 iPSC with a p=0.048 calculated, whilst CLN7 iPSCs all displayed 
significant differences to Shef3 cell with a p=0.047 calculated. (D) CLN7 iPSCs displayed 
significant differences in expression when compared to both Shef3 and HEK29, with p-
values of p=0.026 and p=0.038 calculated, respectively. (E) Control iPSCs displayed 
significant differences between each cell type with a p value of p=0.034, p=0.045 and 
p=0.039 respectively. Subsequently, error bars are calculated based on the standard error 
mean (SEM) of each sample.  
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4.4 Neural Differentiation and Specification  
4.4.1 Neural Differentiation 
Following successful reprogramming of NCL patient and healthy somatic cells to induced 
pluripotent stem cells, a neural differentiation protocol developed within the McKay lab 
was implemented in order to produce viable neural progenitor cells and neurons in order 
to successfully observe phenotypic changes of during neural development. In order to 
initiate neural differentiation, feeder free patient CLN7 and control iPSCs were subjected 
to a stepwise protocol which allowed for the minimization of induction of exogenous 
growth factors, thus encouraging differentiation of neuroectoderm. Figure 14 (below) 
demonstrates the sequential steps during neural differentiation. At day 0 feeder free 
CLN7 and control iPSCs were enzymatically dissociated through the use of TrypLE express 
and re-suspended in neural induction media containing enhanced FGF2 levels of 20ng/mL 
(see table 5). Within 24 hours neuroepithelial-like clusters (NECs) formed with highly 
proliferative characteristics. Following the formation of these epithelial clusters, on day 6, 
NECs were replated onto laminin coated plates until formation of neural rosettes. 
Following this, neural rosettes were disturbed using a 12-gauge syringe and once again 
replated until a neural progenitor cell monolayer formed. Once an NPC monolayer had 
fully formed and reached a desired confluency, cells were trypsinised, centrifuged and 
replated onto laminin coated dishes, resuspended in neural maturation media for 
terminal differentiation. Cells required a half media change every three days until 
formation of neurons. 
Figures 15 and 16 demonstrate magnified images of the stages of neural differentiation 
outlined above, from maintain feeder free iPSCs to NPC monolayer formation. Both 
figures outline the same time points and stages categorized throughout (A-F) in CLN7 
iPSCs (figure 15) and control iPSCs (figure 16). (A) 10x magnified image of maintenance of 
feeder-free iPSCs. (B) 20x magnified image of neuroepithelial layer. (C) neural rosette 
formation. (D) the expansion of neural progenitor cells as neurospheres. (E,F) monolayer 
formation and expansion of neural stem/progenitor cells.  
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Figure 14: Neural Differentiation Protocol 
Figure 14. A schematic depiction, demonstrating the stepwise protocol for neural 
differentiation.  
 
 
 
 
 
 
 
 
 
Figure 15: Stepwise neural differentiation of CLN7 patient iPSCs in vitro 
Figure 15. Figure represents neural differentiation of CLN7 iPSCs. 
(A)Feeder free iPSCs maintained in mTESR on matrigel covered plates, D0. (B) Increased 
magnification of neuroepithelial cells in suspension, d6. (C) Cells move towards formation 
of neuroepithelial rosettes cultured on laminin-coated plates, D7-10. (D) Expansion of 
neural progenitor cells in suspension as neurospheres. (E, F) Neural progenitor cells 
trypsinised and re-plated at a seeding density of ~50,000 cells, to move towards terminal 
differentiation.    
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Figure 16: Stepwise neural differentiation of Control iPSCs in vitro. 
Figure 16. Figure represents neural differentiation of Control iPSCs.  
(A)Feeder free iPSCs maintained in mTESR on matrigel covered plates, D0. (B) Increased 
magnification of neuroepithelial cells in suspension, d6. (C) Cells move towards formation 
of neuroepithelial rosettes cultured on laminin-coated plates, D7-10. (D) Expansion of 
neural progenitor cells in suspension as neurospheres. (E, F) Neural progenitor cells 
trypsinised and re-plated at a seeding density of ~50,000 cells, to move towards terminal 
differentiation 
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4.4.2 CLN7 and Control NPCs Exhibit Loss in Pluripotent Markers and an Increase in Nestin 
Following qualitative assessment of induced pluripotent stem cells, as well 
as qPCR analysis of various metabolic genes, quantitative PCR was 
implemented for further validation of the iPSCs using potency markers 
Sox2 and Lin28. This assessment also allowed for the comparison of 
differing potency markers for NCL patient lines (CLN7) in comparison to 
their wildtype counterparts, whilst allowing to compare against 
differentiated NPCs in order to validate successful differentiation towards 
NSCs/NPCs.  
 The protein Nestin is expressed extensively in the NPCs of normal adult 
brains and is said to be replaced by other neuron specific protein upon 
differentiation towards neuronal cells (Hendrickson et al., 2011). Nestin is 
distributed within neural progenitor cells of the sub-ventricular zone of the 
lateral ventricle as well as within the subgranular zone of the denate gyrus 
as (Hendrickson et al., 2011). The apparent presence of nestin within 
neuronal progenitor cells, whilst deregulated in neurons makes it an ideal 
target for identification of successful differentiation towards NPCs. 
Therefore, this made the gene a prime target as to confirm our cells as 
NPCs in conjunction with the loss of pluripotency markers.  
Figures 17 and 18 (below) depict the differential expression of the 
pluripotency markers SOX2 and LIN28A in CLN7 and control NPCs in 
comparison with iPSC counterparts as well as Shef3 and HEK293 controls. 
Both figures show a statistically significant decrease in both pluripotency 
markers in CLN7 and control NPCs compared to their iPSC counterparts, 
with CLN7 iPSCs displaying a 73-fold increase in LIN28A expression and an 
8-fold increase in SOX2 expression compared to NPC counterparts. Control 
iPSCs display a 46-fold increase in LIN28A expression and 173-fold increase 
in SOX2 expression when compared to NPC counterpart. In conjunction, 
figure 18 depicts the differential expression of neural stem/progenitor cell 
marker, Nestin. Figure 19 shows a significant increase in expression of the 
marker in both CLN7 and control NPCs compared to their iPSC 
counterparts, with a 15.5-fold and 3.7-fold increase in Nestin expression in 
control NPCs and CLN7 NPCs, respectively, compared to iPSC counterparts.   
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Expression of genes was determined via the implementation of relative 
expression. This method determines expression through comparing Ct 
values of target cells normalized to housekeeper, in our case PABC4 via 
CT (mean of target CT – mean of housekeeper CT). The normalized Ct 
values are converted to relative expression utilizing the formula 2CT with 
the values expressed relative to those of control iPSCs.  
 
 
 
 
 
 
 
 
 
 
 
Figure 17: LIN28A qPCR Analysis in iPSCs and NPCs 
Figure 17. Differential expression of LIN28A between CLN7 and Control iPSCs in 
comparison to neural progenitor cell counterparts as well as Shef3 embryonic stem cells 
and HEK293 cells. Relative expression was determined of CLN7 iPSCs against control cell. 
Subsequently single factor ANOVAs were performed with post-hoc Tukey analysis 
performed in order to determine statistical significance between groups. Analysis 
performed calculated a statistical difference between control iPSC and control NPC groups 
of p=0.025, with CLN7 iPSC and CLN7 NPC displaying a significance of p=0.049. The graph 
depicts the relative expression of three biological repeats with each repeat also involving 
three technical repeats. Subsequently, error bars are calculated based on the standard 
error mean (SEM) of each sample.  
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Figure 18: SOX2 qPCR Analysis in iPSCs and NPCs 
Figure 18. Differential expression of SOX2 between CLN7 and Control iPSCs in comparison 
to neural progenitor cell counterparts as well as Shef3 embryonic stem cells and HEK293 
cells. Relative expression was determined of CLN7 iPSCs against control cell. 
Subsequently, single factor ANOVAs were performed with post-hoc Tukey analysis 
performed in order to determine statistical significance between groups. Analysis 
performed calculated a statistical difference between control iPSC and control NPC groups 
of p=0.008, with CLN7 iPSC and CLN7 NPC displaying a significance of p=0.028 The graph 
depicts the relative expression of three biological repeats with each repeat also involving 
three technical repeats. Subsequently, error bars are calculated based on the standard 
error mean (SEM) of each sample. 
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NESTIN 
 
 
 
 
 
 
 
 
Figure 19: Nestin qPCR Analysis in iPSCs and NPCs 
Figure 19. Differential expression of Nestin between CLN7 and Control iPSCs in 
comparison to neural progenitor cell counterparts as well as Shef3 embryonic stem cells 
and HEK293 cells. Relative expression was determined of CLN7 iPSCs against control cell. 
Subsequently, single factor ANOVAs were performed with post-hoc Tukey analysis 
performed in order to determine statistical significance between groups. Analysis 
performed calculated a statistical difference between control iPSC and control NPC groups 
of p=0.004, with CLN7 iPSC and CLN7 NPC displaying a significance of p=0.002 The graph 
depicts the relative expression of three biological repeats with each repeat also involving 
three technical repeats. Subsequently, error bars are calculated based on the standard 
error mean (SEM) of each sample.  
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The evident increase in expression of neural stem/progenitor cell marker, Nestin, in the 
CLN7 and control NPCs compared to iPSCs, whilst the expression of potency markers; 
SOX2 and LIN28A decreased, suggests successful differentiation to neural 
progenitor/stem cells. Our results show statistical significance in each target between 
our CLN7 and control NPCs with their corresponding iPSC cell line. Quantitative PCR was 
performed on the NPCs in order to ascertain any differences in metabolism. As previously 
aforementioned, iPSCs show negligible differences in metabolism, however, previous 
data has suggested that no phenotypic differences have been observed between CLN7 
iPSCs and controls, with hypothesized disparities expected as the neural differentiation 
pathway continues.  
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4.5 CLN7 NPCs Show A Metabolic Shift Towards Glycolysis 
 
We hypothesized that the neural progenitor cells of CLN7 would show a 
change in metabolic modality. Current literature shows that healthy NPCs 
move towards oxidative phosphorylation (OXPHOS) in order for complete 
differentiation towards neurons, which rely completely on OXPHOS to 
meet energy requirements. OXPHOS has been shown to cause an increase 
in oxidative stress through the increase in ROS production through oxygen 
free radicals, this led to the introduction of the human oxygenase (HO-1) 
marker to be implemented. HO-1 is an oxidative stress marker prevalent in 
circumstances of increased ROS production. ATP synthase is known to be 
the main energy source of metabolic pathways, with the marker relating to 
the fifth multi subunit OXPHOS complex. The enzyme synthesizes ATP 
derived from ADP within the mitochondrial matrix, utilizing energy 
provided by the proton electrochemical gradient. (Jonckheere, Smeitink 
and Rodenburg, 2012). Upregulation of ATP synthase relates to an increase 
in OXPHOS. In conjunction to this, an upregulation of Mitochondrial 
uncoupling protein 2 (UCP2) relates to an increase in OXPHOS. UCP2 is a 
member of the anion carrier proteins, the carriers are able to facilitate the 
transfer of anions from the inner mitochondrial membrane and the return 
transfer of protons from the outer to the inner mitochondrial membrane 
(Sreedhar et al., 2017). 
Moreover, the shift towards glycolysis was of great interest in the project 
as a shift towards this metabolic state would indicate cell dysfunction 
leading to less efficient energy production. The markers GLUT1, PKM2 and 
LDHA are all required in the various steps of glycolysis. Glucose Transporter 
1 (GLUT1) is a uniporter protein found within mammalian cells that 
facilitates the transport of glucose across the plasma membrane and has 
been shown to regulate cell glycolysis in prostate cancer (Xiao et al., 2018). 
The pyruvate kinase muscle isozyme M2 (PKM2) is a glycolytic limiting 
enzyme which catalyzes the final step in glycolysis of the 
transphosphorylation between phosphoenolpyruvate and adenosine 
diphosphate resulting in the formation of ATP and pyruvate (Dong et al., 
63 | P a g e  
 
2016). The protein encoded by the LDHA gene catalyzes the conversion of 
L-lactate and NAD+ to pyruvate and NADH in the final step of glycolysis, a 
key component in the regulation of glycolytic pathway (Jin et al., 2017). 
Inflammation of neuronal cells and NPCs has been shown to lead to a 
variety of neurodegenerative diseases. In order to ascertain whether there 
is an upregulation of inflammation in CLN7 NPCs and iPSCs, qPCR analysis 
of the NFkB1 pathway was undertaken. The nuclear factor, NFkB pathway 
has been shown to be a prototypical proinflammatory pathway due to its 
role in the expression of proinflammatory genes such as adhesion 
molecules, cytokines and chemokines (Lawrence, 2009).  
Figure 20 (A-F) (below), demonstrates alterations in the metabolic profile 
of CLN7 NPCs compared to controls. CLN7 NPCs show an increase in 
expression of inflammatory marker, NFB, with an increase in relative 
expression of 1.54-fold. A shift towards glycolysis is implied via the results 
as the glycolytic enzyme, PKM2, demonstrates an increase by 2.1-fold in 
relative expression in CLN7 NPCs compared to controls. Moreover, there is 
an increase in the relative expression in both ATP synthase and GLUT, with 
a 10.6-fold and 16.2-fold increase, respectively. The results indicate 
changes in oxidative stress and the antioxidant response in CLN7 NPCs, 
with 7.8-fold increase in the relative expression of SIRT1 in CLN7 NPCs 
compared to controls, however, there was decrease in expression of 
oxidative stress marker, HO-1. Control NPCs demonstrated a 5.9-fold 
increase in expression of HO-1 compared to CLN7 NPCs. All results 
obtained show statistical significance of p<0.05 (see legend).  
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Figure 20: Metabolic Targets in NPCs 
Figure 20. Differential expression of (A) NFB, (B) HO-1, (C) PKM2, (D) ATP 
Synthase, (E) GLUT1 and (F) SIRT1 (n=3, three technical repeats) between CLN7 
neural progenitor cells (NPCs) against healthy controls. Subsequently, 
Independent T-Tests were performed in order to determine statistical significance 
between the two cell types, with the following p values calculated; (A) p=0.008, 
(B) p=0.04, (C) p=0.02, (D) p=0.03, (E) p=0.04, (F) p=0.02. Subsequently, error bars 
are calculated based on the standard error mean (SEM) of each NPC sample.  
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Table 19: Summation of Gene Expression of Metabolic Targets in NPCs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Target Relative Expression 
of CLN7 NPCs 
compared to 
normalized control 
NPCs 
Significance 
NFB 1.54 P=0.008 
Ho-1 0.17 P=0.04 
PKM2 2.1 P=0.02 
ATP Synthase 10.6 P=0.03 
GLUT1 16.2 P=0.04 
SIRT1 7.8 P=0.02 
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4.6 CLN7 NPCs Show a Decrease in Autophagic Flux  
The antibody p-p70 was normalized to p70 in order to provide an insight 
into the fold change in the upregulation of activated p70 in NPCs. As stated 
previously, accumulation of p62 is indicative of impaired autophagy. The 
protein, p70 is a downstream target of the mammalian target of rapamycin 
complex 1 (mTORC1) which is phosphorylated upon activation of the 
pathway. The mTORC1 pathway has been shown to be intrinsically linked 
to autophagy, with an upregulation in mTORC1 resulting in a 
downregulation of autophagy. An accumulation of p70 and activated p-p70 
is indicative of alteration in autophagic flux.  
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Figure 21: Western Blot analysis of autophagy related proteins to monitor changes of autophagic flux in CLN7 NPCs 
compared to Controls 
Figure 21: Western Blot Analysis of Autophagic flux in CLN7 NPCs compared to Controls, 
Figure 42. Western blot analysis of changes in (A) P70 normalised to -actin housekeeper, 
(B) p-p70 with expression normalised against p70 and (C) p62 normalised to -actin 
housekeeper. 20µg of each sample was loaded and electrophoresed along a 10% SDS-
PAGE acrylamide gel at 90v for 1.5-2 hours. Figure represents densitometry analysis of 
western blots performed via Image J. Results show normalised expression to -actin/p70 
(stated), from which fold change was calculated in CLN7 neural progenitor cells relative to 
Control NPCs as well as analysis of CLN7 HDF and NHDF controls. The image represents 
western blot experiment carried out with three technical repeats for quality control 
purposes. 
Figure 21 (A-C) demonstrates the accumulation of proteins related to an impairment of 
autophagy in CLN7 NPCs compared to control NPCs. Analysis was conducted against CLN7 
HDFs and control nHDFs in order to ascertain any differences in accumulation of target 
proteins as differentiation progresses. Western blot analysis shows a 3.8-fold increase in 
mTOR target, p70, in CLN7 NPCs compared to control NPCs. However, CLN7 HDFs and 
nHDFs show little differences in p70 expression between each other, with a 3.3-fold and 
4-fold increase respectively. Phosphorylated p70 (p-p70), displays a 1.4-fold increase in 
expression in CLN7 NPCs compared to controls, whereas CLN7 HDFs and nHDFs displayed 
a near identical expression, with a fold increase of 1.89 and 1.88 respectively. Impairment 
of autophagy has been linked to increased p62 accumulation, our results show a 7.8-fold 
increase in p62 levels in CLN7 NPCs compared to those of control counterparts, 
conversely, CLN7 HDFs show a decrease in p62 levels compared to nHDFs with a fold-
change of 1.95 and 12, respectively, obtained.  
The results are indicative of an accumulation of proteins intrinsically linked with impaired 
autophagy and defective lysosomal breakdown in neural progenitor cells. The results also 
indicate that this is not apparent in HDF CLN7 cell when compared against healthy 
controls, suggesting that changes in autophagic flux are only observable the further 
down the differentiation pathway, as with observing changes in metabolic shift.  
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4.7 Terminal Differentiation of CLN7 474 NPCs 
Once patient CLN7 and control cells had differentiated into neural 
progenitor cells, they underwent terminal differentiation on laminin 
coated plates. There are current issues with neural differentiation in 
obtaining both high yield and purity of neurons due to various factors with 
neural differentiation protocol robustness. Due to extenuating 
circumstances, issues arose when terminally differentiating both CLN7 and 
control NPCs. Due to this, only CLN7 474 NPCs were able to terminally 
differentiate to neurons. The cells were cultured for a further 28 days in 
neural maturation media until mature neurons had formed. Figure 21 
(below) depicts microscopic image at magnification of x10 of initial 
formation of CLN7 neurons derived from CLN7 474 neural stem/progenitor 
cell via neural differentiation protocol. 
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Figure 22: Terminal differentiation of CLN7 patient NPCs derived from iPSCs. 
Figure 22. Figure depicts final stage of neural differentiation protocol of CLN7 NPCs. 
(A,B) Images taken of CLN7 derived neurons produced through a stepwise neural 
differentiation protocol. NPCs were seeded at a density of ~50,000 cells and cultured on 
laminin-coated plates in neural maturation media until formation of mature neuronal 
cells.  
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4.7.1 CLN7 Neurons Exhibit Accumulation of Autophagic Related Proteins 
Immunocytochemistry was implemented in order to assess p62 and LAMP1 
accumulation within neuronal vesicles as well as known neural marker, β-
III-Tubulin, and mitochondrial marker, Mitotracker Red. Cells were also 
incubated with DNA stain, DAPI, in order to visualize nucleus of the 
neuronal cells. Images shown below are that of CLN7 patient derived 
neuronal cells due to technical issues in terminal differentiation of 
controls. Immunocytochemistry was performed on neurons utilizing the 
Autophagic markers p62 and LAMP1. Lysosomes acts as degradation hubs 
for autophagic and endocytic components in order to maintain cellular 
homeostasis, essential for neuronal cell survival and function (Huynh et al., 
2007). LAMP1 is distributed throughout autophagic and endolysosomal 
organelles and is degraded upon activation of autophagic pathways. 
LAMP1 is routinely used as am autophagic marker, with an accumulation of 
the protein related to impaired autophagy (Eskelinen, 2006). The presence 
of the protein within the CLN7 neurons is an indicator of autophagic arrest. 
As well as LAMP1, the protein p62 has been established as a marker of 
impaired autophagy through extensive studies. The protein acts as a 
receptor for autophagy and a scaffold for the degradation of ubiquitin 
cargos. Although the protein aids in the delivering of deleterious products 
to autolysosomes for degradation, p62 itself is also degraded during the 
process (Katsuragi, Ichimura and Komatsu, 2015). An accumulation of the 
protein within neuronal peripherals has been used in previous research as 
an autophagic impairment marker.  
Figures 23 and 24 demonstrate ICC staining of CLN7 474 neurons, probed 
for p62 (red) and LAMP1 (green). Images show accumulation of p62 within 
the vesicles of the neurons and LAMP1 in the axons of the neurons, 
indicative of accumulation and storage of autophagy related proteins 
within the patient neurons. With neurons stained with nuclear stain, DAPI 
(blue) in order to visualize nuclei of the various neuronal cells.  
Β-III-tubulin is a member of the tubulin family and is one of the two core 
protein families (alpha and beta tubulins) that is able to heterodimerize 
and assemble to form microtubules (Katsetos et al., 2003). The protein has 
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been established to be expressed is neurons primarily and involved in 
neurogenesis and axon guidance with maintenance properties (Dráberová 
et al., 2008). Immunocytochemistry utilizing this marker was imperative in 
order to confirm successful differentiation to neurons.   
Figure 26 depicts ICC staining for B-III-tubulin in CLN7 474 neurons. The 
image shows positive staining result (red) within the axons of the neurons, 
a good indication of successful differentiation to neurons from neural 
stem/progenitor cells. 
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Figure 23: CLN7 Neuronal Cells ICC Dual Stain of p62 and LAMP1:  
Figure 23. Immunocytochemistry image produced depicts CLN7 neurons developed 
through terminal differentiation of neural progenitor cells. Neuronal cells were incubated 
with LAMP1 (green) and p62 (red) primary antibody at a dilution of 1:200 for a minimum 
of ~12 hours at 4OC, followed by the incubation of Alexa Fluor 488 rabbit (emission 
519nm) and Alexa Fluor 568 mouse (emission 601nm) secondary antibodies, respectively. 
Following this, cells were also incubated with DNA stain, DAPI (emission 453nm) in order 
to visualize nucleus. Arrows show the accumulation of LAMP1 (green) in the axons of the 
neurons, whilst arrows directed towards p62 (red) display accumulation within vesicles, 
an indicator of impaired autophagy. Images shown at x20 magnification, whilst scale bar 
displayed at 100m. 
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Figure 24: p62 & Lamp1 ICC Staining of Neuronal Cells 
Figure 24. Immunocytochemistry image produced depicts CLN7 neurons developed 
through terminal differentiation of neural progenitor cells. Neuronal cells were incubated 
with LAMP1 (green) and p62 (red) primary antibody at a dilution of 1:200 for a minimum 
of ~12 hours at 4OC, followed by the incubation of Alexa Fluor 488 rabbit (emission 
519nm) and Alexa Fluor 568 mouse (emission 601nm) secondary antibodies. Following 
this, cells were also incubated with DNA stain, DAPI (emission 453nm) in order to visualize 
nucleus. White arrows show the accumulation of LAMP1 (green) in the axons of the 
neurons, whilst yellow arrows directed towards p62 (red) display accumulation within 
vesicles, an indicator of impaired autophagy. Images shown at x20 magnification, whilst 
scale bar displayed at 100m.  
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Figure 25: MitoTracker & Lamp1 ICC Staining of Neuronal Cells 
Figure 25. Immunocytochemistry image produced depicts CLN7 neurons developed 
through terminal differentiation of neural progenitor cells. Neuronal cells were incubated 
with LAMP1 (green) and at a dilution of 1:200 for a minimum of ~12 hours at 4OC, 
followed by the incubation of Alexa Fluor 488 rabbit secondary antibody (emission 
519nm) in addition to incubation of MitoTracker (red) (emission 644nm), in order to 
assess mitochondria utilizing mitochondrial membrane potential. Following this, cells 
were also incubated with DNA stain, DAPI (emission 453nm) in order to visualize nucleus. 
White arrows show the accumulation of LAMP1 (green) in the axons of the neurons, 
whilst yellow arrows directed towards MitoTracker (red) within mitochondria. Images 
shown at x20 magnification, whilst scale bar displayed at 100m.  
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Figure 26: B-III-tubulin ICC Staining of Neuronal Cells 
Figure 26. Immunocytochemistry image produced depicts CLN7 neurons developed 
through terminal differentiation of neural progenitor cells. Neuronal cells were incubated 
with neural marker, -III-tubulin at a dilution of 1:200 for a minimum of ~12 hours at 4OC, 
followed by the incubation of Alexa Fluor 568 mouse secondary antibody (emission 
601nm) at a dilution of 1:500. Images shown at x20 magnification, whilst scale bar 
displayed at 100m.  
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5.0 Discussion 
The aim of this project was to utilize current techniques and technologies 
in neural differentiation to successfully produce neural progenitor cells and 
neurons via differentiation of patient CLN7 induced pluripotent stem cells 
and controls. The purpose of developing these cells was to deduce 
phenotypic changes between CLN7 and controls and thus infer any 
differences in autophagic function. Our feeder free CLN7 and control iPSCs, 
provided by the McKay lab, were subjected to a stepwise neural 
differentiation protocol, which encouraged the differentiation and 
proliferation of neuroectoderm through minimizing the exposure to 
exogenous growth factors. Once neural progenitor cells were cultured 
during differentiation, both RNA and protein were extracted in order to 
undergo molecular analysis through techniques such as; western blot 
analysis, RT-PCR and qPCR in order to deduce the accumulation of specific 
proteins and expression of various genes.  
5.1 Successful Derivation of iPSCs Through Somatic Reprogramming 
The results indicate the successful development of neural progenitor cells 
in both CLN7 and control cells as well as successful differentiation to 
neurons of the patient CLN7 cells. Western blot, qPCR and RT-PCR analysis 
show clear differences in gene expression and protein accumulation 
between the two cell lineages. As previously stated, there is limited 
information regarding CLN7 disease and the mechanisms involved in 
disease progression through maturation of neural cells. The data produced 
indicates significant differences in accumulation of autophagy related 
proteins and the expression of various genes related to metabolism, 
oxidative stress and inflammation in CLN7 NPCs, whilst CLN7 iPSCs 
displayed expression of the various genes comparable to healthy controls.  
Prior to the implementation of neural differentiation, the induced 
pluripotent stem cells of both and CLN7 and control cell lines were 
validated for pluripotency markers via immunocytochemistry and RT-PCR. 
The presence of pluripotency markers Sox2, Tra-1-81 and Oct4 was 
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confirmed in both feeder iPSCs (iPSCs on MEFs) and feeder free iPSCs. RT-
PCR was able to qualitatively assess the gene expression of pluripotency 
markers Oct4, Nanog and Lin28A as well as E-cadherin, a key regulator of 
pluripotency and self-renewal in iPSCs and embryonic stem cells. Through 
this assessment, it could be deduced that the CLN7 and control iPSCs 
displayed gene expression of these markers, which was akin to those of 
embryonic stem cells. The data collected from both immunocytochemistry 
and RT-PCR demonstrated validated iPSC lines with apparent pluripotency 
characteristics.  
5.2 Successful Derivation of NPCs Confirmed by qPCR 
The project aimed to deduce any differences in phenotype of neural 
progenitor cells of CLN7 compared to healthy counterparts. Successful 
derivation of NPCs was confirmed by qPCR analysis of pluripotency 
markers, LIN28A and SOX2 in NPCs compared to that of iPSCs. Data 
collected displayed a loss in the pluripotency markers through neural 
differentiation with LIN28A showing an increase in relative expression in 
CLN7 iPSCs and control iPSCs compared to their NPC counterparts, with a 
73-fold and 50-fold increase respectively, with a statistical significance of 
p=0.002 and 0.02 respectively. There was also an increase in relative 
expression of SOX2 in iPSCs compared to their NPC counterparts. CLN7 
iPSCs had 8-fold increase in expression levels with a strong statistical 
significance of p=0.003 whereas control iPSCs displayed a 124-fold increase 
in gene expression of SOX2, also displaying a strong statistical significance 
of p=0.0005.  
The neural progenitor cell marker, Nestin was also utilized in order to 
evaluate differentiation efficacy. A 3.7-fold increase in relative gene 
expression of CLN7 NPCs compared to CLN7 iPSCs was observed with a 
statistical significance of 0.04. Indeed, control NPCs also displayed 
comparative levels of increase in relative gene expression with a 15.5-fold 
increase observed with a statistical significance of 0.01. The loss of 
pluripotency markers LIN28A and SOX2, coupled with the increase in NPC 
marker, Nestin, confirms the successful differentiation of iPSCs to NPCs in 
both CLN7 cells and healthy controls.  
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5.3 Upregulation in the Inflammatory Response in CLN7 NPCs and Neuronal Cells 
 It was apparent there was an increase in gene expression of NFkB1 in 
CLN7 neural progenitor cells, with a 1.54 times upregulated expression in 
CLN7 NPCs compared to that of control NPCs with a strong significance of 
p=0.008. The nuclear factor, NFkB pathway has been extensively 
researched in relation to the inflammatory response. This pathway has 
long been considered a prototypical proinflammatory signaling pathway, 
this has been evident during the activation of this pathway by the tumor 
necrosis factor α (TNFα) and proinflammatory cytokines, e.g. interleukin 1 
(IL-1) (Lawrence, 2009). The inflammatory response is characterized by the 
coordinated activation of various signaling pathways, such as that of NFkB 
which has been shown to exist through the activation of both canonical 
and alternative pathways (Liu et al., 2017).  
In addition, extensive research has shown that the scaffold protein and 
autophagy receptor, p62, activates the NFkB pathway (Katsuragi, Ichimura 
and Komatsu, 2015). p62/SQSTM1 (hereafter p62) is an evolutionary 
conserved, stress-inducible, cellular protein among multicellular 
organisms. P62 has been reported to act as a receptor for autophagic cargo 
via interactions with ubiquitinated proteins and LC3 (Liu et al., 2016). P62 
distribution is found within the cytoplasm, but also localizes in the nucleus, 
autophagosomes and lysosomes (Chen et al., 2014). Research has 
demonstrated that p62 is degraded during autophagy, in NCL patients, a 
significant accumulation of p62 has been observed due to an impairment 
of this physiological process, preceded by the formation of p62 and 
ubiquitin positive aggregate structures (Mohammed et al., 2017). The 
adaptor protein, p62, plays a critical role in selective autophagy and 
demonstrates multiple domains (see figure 3), including the ubiquitinated-
associated domain (UBA), which results in the formation of dimers that are 
destabilised by ubiquitin binding (Katsuragi, Ichimura and Komatsu, 2015). 
As well as its role in autophagy, p62 acts as a scaffold protein in NFkB 
activation. The inflammatory pathway is activated via the binding of p62 
with atypical PRKC, RIPK1 (receptor (TNFRSF)- interacting serine-threonine 
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kinase 1) or tumour necrosis-associated factor 6 (TRAF6) through the PB1, 
zinc finger (ZZ) or TRAF6 (TB) domains respectively (see figure 19) 
(Katsuragi, Ichimura and Komatsu, 2015).   
 
  
 
 
 
 
 
Westerns:  
Figure 27: p62 domains 
 
 
 
 
 
 
5.4 Autophagic Flux is Reduced in CLN7 Neural progenitor and Neuronal Cells 
In addition to qPCR analysis of NFkB1 expression, western blot analysis was implemented 
in order to give a semi-quantitative assessment of p62 accumulation in CLN7 NPCs 
compared to that of the control NPCs. There was an apparent increase in p62 
accumulation in progenitor cells of CLN7 when compared to that of control, healthy NPCs 
when analyzed through western blot analysis, with a 7.8-fold increase observed in CLN7 
NPCs. Immunocytochemistry also displayed a clear accumulation of p62 within the 
peripherals of the CLN7 derived neurons. P62 and its accumulation within neural cells has 
been shown to be indicative of impaired autophagy, an inducible development within 
CLN7 and neuronal ceroid Lipofuscinoses patients (Steenhuis et al., 2010). Autophagy is 
an evolutionary conserved catabolic pathway, vital for its necessity in physiological 
processes, at the forefront is in which long-lived proteins and damaged organelles are 
 
 
Figure 26. A representation of the domain structures of p62 and its binding partners. P62 and Keap1 are 
able to interact via the KIR and LC3 is able to recognise p62 via the LIR. Atypical PKC (aPKC) and ERK1 
interact with p62 via the PB1 domain, which is able to self-oligomerize and form hetero-oligomers with 
other proteins, which contain a PB1 domain. The ZZ domain associates with RIP and TRAF6-binding domain 
(TB) interacts with TRAF6. TRAF6, RIP and aPKC are thought to be involved in NF-kB activation, mediated by 
p62. The interaction between ERK and p62 is thought to negatively regulate adipogenesis (Katsuragi et al., 
2015) 
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delivered to lysosomes for degradation in order to maintain energy homeostasis 
(Johansen and Lamark, 2011). Autophagy arises when the sequestered proteins and 
organelles forming an autophagosome fuse with a lysosome in order to degrade the cargo 
(Ganley et al., 2011).  
The impairment of autophagy in the CLN7 affected NPCs is supported further through the 
accumulation of p70 and phosphorylated p70 (p-p70) with a fold increase in CLN7 NPCs of 
3.8 and 1.4 respectively. The protein, p70 S6 kinase is a downstream target of the 
mammalian target of rapamycin (mTOR) that is phosphorylated upon activation of the 
mTORC1 pathway (Magnuson, Ekim and Fingar, 2012) (Xiao et al., 2009). The atypical 
serine/threonine kinase, mTOR, is a member of the phosphoinositide 3-kinase related 
kinase family (PI3K) (Laplante and Sabatini, 2012). Interactions between mTOR and 
various proteins results in the formation of two distinct complexes; mTOR complex 1 
(mTORC1) and mTOR complex 2 (mTORC2), these distinct complexes demonstrate 
differing upstream inputs, downstream outputs and sensitivities to rapamycin (Figure 4) 
(Katsuragi, Ichimura and Komatsu, 2015). Both of these complexes are similar in size, with 
mTORC1 having six known protein components whereas mTORC2 contains seven 
(Laplante and Sabatini, 2012). The mTORC1 complex is activated via amino acids on the 
surface of lysosomes, where the assembly of Rag proteins, Rheb, Ragulator, v-ATPase and 
putative amino acid sensors occurs (Figure 5). The subunit of mTORC1, Raptor, was 
identified as a p62-interacting protein with both Raptor and RagC/D shown to be able to 
interact with p62. This interaction is shown to be amino acid-dependent, with an increase 
in amino acid levels leading to the translocation onto lysosomes (Katsuragi, Ichimura and 
Komatsu, 2015). A recent study showed that amino acid stimulation lead to the 
ubiquitination of mTOR through K63-linkage via TRAF6. This interaction has been shown 
to be p62 dependent, resulting in the mTORC1 activation on the lysosome being 
regulated via the K63-ubiquitinated mTOR. However, the mechanisms in which the 
enhancement of TRAF6 activity via amino acids occur is poorly understood. These 
interactions for mTORC1 activation suggest that p62 is a pivotal adaptor in this 
mechanism (Katsuragi, Ichimura and Komatsu, 2015). 
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Figure 28: p62 and mTORC1 
Figure 27. Depiction of the signalling functions of p62 in the activation of mTORC1 pathway, with Raptor, 
RagC and TRAF6 components on the lysosomal membrane. K63-ubiquitination of mTOR via TRAF6 promotes 
the activation of mTORC1. This activation results in the phosphorylation of S6K and ULK1/2, which in turn 
induces protein synthesis and supresses autophagy. The interactions occur in an amino acid-dependent 
manner; however, the amino acid level does not influence localisation of p62 on lysosomes (Katsuragi et al., 
2015) 
Impairment of autophagy can be further inferred through the accumulation of lysosomal 
associated membrane protein 1 (LAMP1) within the CLN7 derived neurons depicted 
through immunocytochemistry. Lysosomes are responsible for the degradation of 
deleterious waste products and fuse with autophagosomes during autophagy in order to 
from autolysosomes for vesicle breakdown and degradation (Brandenstein et al., 2016). 
LAMP1 is a major protein component of the lysosomal membrane, being a type I 
transmembrane protein with a C-terminal cytoplasmic tail, luminal and transmembrane 
domain (Eskelinen, 2006). LAMP1 is considered an autophagic marker with accumulation 
of the protein attributed to autophagy impairment (Huynh et al., 2007). The 
immunocytochemistry data collected shows clearly, the distribution of the protein and its 
accumulation within the axons of CLN7 affected neurons.  
Although the results obtained through western blot analysis and immunocytochemistry 
indicate the validation of impaired autophagy within the CLN7 neural progenitor cells and 
further differentiated neurons, our techniques possess certain limitations. Further 
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western blot analysis for the accumulation of LAMP1 and LC3-II would have provided 
further evidence and corroborated the immunocytochemistry data. Also, as previously 
stated, due to unforeseen circumstances immunocytochemistry data shown only depicts 
immunostaining of CLN7 neurons due to issues with terminal differentiation of control 
NPCs.  
5.5 CLN7 NPCs Show a Metabolic Shift Towards Glycolysis 
Neurons have been shown to rely heavily on oxidative phosphorylation (OXPHOS) in order 
to meet energy demands, with studies showing the shift in glycolysis to OXPHOS in NPCs 
is tightly coupled to differentiation of neurons (Ito and Suda, 2014). Dysfunction within 
mitochondria leading to impaired oxidative phosphorylation has been shown to be 
frequent within neurological conditions and leads to neurodegeneration due to 
insufficient ATP production (Chen et al., 2008) (Hüttemann et al., 2007). The loss of 
lactate dehydrogenase (LDHA) coupled with a switch in pyruvate kinase gene splicing 
from PKM2 to PKM1 is shown to denote the transition from glycolysis in neural 
progenitor cells to OXPHOS in neuronal cells (Steenhuis et al., 2010). Although studies 
have shown that NPCs are less reliant on OXPHOS than neurons, it has been shown that 
the progenitor cells display a reduction in glycolytic consumption in order to differentiate 
towards neurons (Ivanov et al., 2014). CLN7 derived and control neural progenitor cells 
were analysed using a variety of metabolic and glycolytic markers in order to ascertain 
key differences in cellular metabolism. Our results indicate a shift towards glycolysis 
opposed to oxidative phosphorylation in CLN7 NPCs as well as an upregulation in the 
gene expression of CLN7 iPSCs compared to control iPSCs.  
The glycolytic limiting enzyme, pyruvate kinase muscle catalyses glycolysis by the 
irreversible transphosphorylation between adenosine diphosphate and 
phosphoenolpyruvate (PEP) resulting in the production of pyruvate and ATP. This reaction 
leads to the induction of glycolysis (PKM2) or oxidative phosphorylation via alternative 
splicing of the PKM gene’s primary RNA transcript (PKM1) (Ito and Suda, 2014). PKM1 and 
PKM2 possess differences in activity and tissue expression with PKM1 being constitutively 
active in tissues of the muscle and brain, including neurons. Conversely, PKM2 is 
expressed in anabolic functioning tissues such as proliferating and cancerous cells (Gu et 
al., 2016). 
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Figure 29: Regulation of PKM2 
Figure 28. The regulation of the metabolic pathway via PKM2. This pyruvate kinase isoform is less active 
and thus this decreased enzymatic activity in the cytoplasm promotes the accumulatio of upstream 
glycolytic targets and subsequently converts them into the anabolic pathway (Ito and Suda, 2014).  
 
It has been demonstrated in cancer cells that mTOR induces the Warburg effect, a cells 
apparent preference of glycolysis over oxidative phosphorylation through the induction of 
PKM2 as well as other glycolytic enzymes (Ito and Suda, 2014).  There was an increase in 
expression of PKM2 in CLN7 NPCs of 2.1 compared to control counterparts with a 
significance of 0.02 indicating CLN7 patient derived neural progenitor cells favour 
glycolysis. This notion was further supported by an increase in expression of glucose 
transporter 1 (GLUT1) with 16.2-fold increase in its relative expression compared to that 
of controls with a significance of p=0.04.  
Oxidative phosphorylation consists of five multimeric complexes responsible for the 
formation of the mitochondrial respiratory chain (Koopman et al., 2013). This results in 
the transfer of electrons from reducing equivalents to water, thus forming the proton 
gradient across the inner mitochondrial membrane, utilised by the F1F0 ATPase in order to 
drive ATP synthesis (Pattappa et al., 2013). Although this system is more efficient in the 
production of ATP within neural cells, OXPHOS generates reactive oxygen species (ROS) 
within the electron transport chain, thus leading to an increase in oxidative stress (Ivanov 
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et al., 2014) (Schieber and Chandel, 2014). Our study found that there was an 
upregulation of the oxidative stress marker, HO-1 in control NPCs compared to CLN7 
NPCs. Indeed, HO-1 was 5.9 times more highly expressed in control NPCs with a 
significance of p=0.04. This result further supports the notion that CLN7 NPCs undergo a 
metabolic shift towards glycolysis whilst controls move towards OXPHOS for successful 
differentiation to neurons.  
Although our results are indicative of a metabolic shift towards to glycolysis, it is limited 
through utilising qPCR as its primary source of data collection. To further support the 
notion of a metabolic shift towards glycolysis, future efforts should utilise existing 
technologies in the Agilent SeahorseXF Analyzer. Capable of measuring glucose uptake 
and lactate excretion into the surrounding media, the analyser is capable is of measuring 
glycolytic flux in cells in culture. The XF instrument measures the acidification rate 
directly, and reports this as the extracellular acidification rate (ECAR). Firstly, cells are 
incubated in glycolysis stress test medium without glucose or pyruvate, ECAR us then 
measured (Agilent Technologies, 2017). The first injection saturates the medium with 
glucose. The cell catabolise glucose via the glycolytic pathway to pyruvate, producing ATP, 
NADH, H2O and H+. Extrusion of protons into surrounding media causes accelerated 
increase in ECAR (reported as the rate of glycolysis under basal conditions). (Agilent 
Technologies, 2017) Oligomycin is then injected (ATP synthase inhibitor) and shifts energy 
production to glycolysis, subsequent increase in ECAR revealing the cellular maximum 
glycolytic capacity. Finally, 2-deoxy-glucose (2DG) is injected (a glucose analog), inhibiting 
glycolysis via competitive-binding to glucose hexokinase (first enzyme in the glycolytic 
pathway) (Agilent Technologies, 2017).Resultant decrease in ECAR confirms that ECAR 
produced in the experiment is due to glycolysis, difference between glycolytic capacity 
and glycolysis rate defines glycolytic reserve. The corroboration from possible glycolytic 
flux data, would potentially generate greater support for our hypothesis and support 
further our current data.  
5.6 Upregulation of SIRT1 to Combat Oxidative Stress 
 
The NAD+ dependent deacetylase, Sirt1, has been shown to play various roles in cellular 
processes such as; metabolism, cell survival and adaption to cellular stress as well as 
autophagy induction (Salminen, Kaarniranta and Kauppinen, 2013). SIRT1 has been 
extensively studied in vitro in endothelial cell dysfunction and its effect on oxidative 
85 | P a g e  
 
stress, with the complex able to produce an antioxidant response by modulating the 
expression of oxidative stress protection genes, however the mechanisms in which SIRT1 
facilitates this response is largely unknown (Salminen, Kaarniranta and Kauppinen, 2013) 
(Chang and Guarente, 2014). Subsequently studies into understanding its antioxidant 
effect have been explored with research demonstrating that the transcription factors 
FoxO3a and PGC-1α induce this response (Chan et al., 2017). Studies regarding autophagy 
have demonstrated that increased ROS production and subsequent increase in oxidative 
stress induce autophagy (Ou et al., 2014) (Liemburg-Apers et al., 2015). ROS are highly 
reactive molecules that are produced as a byproduct via cellular metabolism. An increase 
in ROS production due to dysregulation or disease leads to oxidative stress when ROS 
formation exceeds antioxidant response (Schieber and Chandel, 2014). Oxidative stress 
has been shown to result in the accumulation of autophagosomes through signal 
transduction regulation via ROS signaling (Liemburg-Apers et al., 2015). As previously 
stated, HO-1 expression is significantly decreased in CLN7 NPCs, indicating a decrease in 
ROS production with a 7.8-fold increase in SIRT1 expression in CLN7 NPCs also shown. 
This indicates that SIRT1 overexpression in the CLN7 NPCs is resulting in an antioxidant 
response, this reduction in oxidative stress, confirmed by downregulation in HO-1 may be 
resulting in a reduction in autophagosome accumulation and trafficking leading to an 
impairment of autophagy.  
 As previously mentioned, CLN7 is thought to share sequence homologies with the major 
superfamily of active transporters (Kousi et al., 2009). Neuronal ceroid lipofuscinosis 
disorders are characterized by the accumulation of lysosomal storage material- lipofuscin, 
composed of subunit c of mitochondrial ATP synthase (Cárcel-Trullols, Kovács and Pearce, 
2015). CLN7 neural progenitor cells were shown to have a 10.6-fold increase in ATP 
synthase expression with a statistical significance of 0.03. ATP synthase catalyzes the 
terminal step of oxidative phosphorylation and synthesizes ATP from adenosine 
diphosphate (ADP) and Pi. Proton translocation (Junge and Nelson, 2015). This increase in 
CLN7 NPCs would suggest that there is an increase in OXPHOS; however, our data 
contradicts this notion. Therefore, it could be inferred that this increase in ATP synthase 
could be due to mitochondrial dysfunction, resulting in the signal to transduce and 
overexpress ATP synthase in these CLN7 NPCs (Inoue et al., 2010). As these NPCs favor 
glycolysis, ATP synthase accumulates and is unable to be degraded due to impaired 
autophagy as shown in previous results. This would lead to an accumulation in storage 
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material within neural progenitors and resulting neurons, with lipofuscin shown to be 
composed of subunit c of mitochondrial ATP synthase, which implies this could be the 
mechanism behind the accumulation of this material.  
Our results are indicative of an antioxidant response in CLN7 NPCs, shown to be 
confirmed by a decrease in the expression of HO-1, compared to control NPCs. However, 
as with our aforementioned data displaying a metabolic shift towards glycolysis, our data 
is limited by qPCR being the primary source of data. In order to confirm our results, 
further oxidative stress experiments should be performed in order to confirm our results. 
The SeahorseXF Analyzer Mitostress kit by Agilent, is capable of measuring mitochondrial 
function, by directly measuring oxygen consumption rate (OCR) with the assay providing 
insight into mitochondrial dysfunction and functional differences between cell types. The 
assay performs functional analysis through the use of built in injection ports in order to 
add modulators of respiration (Oligomycin, Carbonyl cyanide-4 (trifluoromethoxy) 
phenylhydrazone (FCCP), Rotenone and Antimycin) into the cell wall during the assay to 
reveal parameters of mitochondrial function (Agilent Technologies, 2019). Oligomycin is 
first injected, inhibiting ATP synthase, impacting/decreasing the electron flow through the 
electron transport chain (ETC), thus reducing mitochondrial respiration or OCR, linked to 
ATP production (Agilent Technologies, 2019). FCCP is then injected, collapsing the proton 
gradient, disrupting the mitochondrial membrane potential. Thus, electron flow through 
ETC is uninhibited and oxygen consumption reaches maximum. FCCP-stimulate OCR can 
then be used to calculate spare respiratory (ability of cell to respond increased energy 
demand or under stress) capacity (defined as; difference between maximal respiration 
and basal respiration) (Agilent Technologies, 2019). Lastly, rotenone and antimycin A (a 
complex III inhibitor) are injected, shutting down mitochondrial respiration and allowing 
nonmitochondrial respiration driven by processes outside the mitochondria to be 
calculated (Agilent Technologies, 2019).  
5.7 Impaired Autophagy Lead to an Upregulation of the NFB Pathway, 
Resulting In a Decrease In ROS Production 
The results obtained indicate the activation of both the mTORC1 and NFkB 
pathway in CLN7 patients via sequestered p62 accumulation. The protein 
p62 has been proven to be an NFkB agonist through its binding with 
atypical PRKC, RIPK1 (receptor (TNFRSF)- interacting serine-threonine 
kinase 1) or tumour necrosis-associated factor 6 (TRAF6) through the PB1, 
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zinc finger (ZZ) or TRAF6 (TB) domains respectively (Katsuragi, Ichimura 
and Komatsu, 2015). The accumulated p62 is also able to interact and 
upregulate the mTOR pathway, with both Raptor and RagC/D shown to be 
able to interact with p62 (Duran et al., 2011). This interaction leads to the 
phosphorylation of the downstream target, p70 S6 kinase resulting in a 
downregulation of autophagy (Xiao et al., 2009). The results produced 
indicate the importance of p62 and its intrinsic link in both autophagy 
impairment and increase in inflammation. Upregulation in inflammation 
within neural cells has proven to be a key component of 
neurodegeneration in biomedical research, thus this upregulation could be 
a key component of the degeneration in CLN7 patients including motor 
and cognitive regression due to neuronal cell death via the inflammatory 
response (Aktas et al., 2007).  
Our results are indicative of an increase in the antioxidant response in 
CLN7 NPCs with significant decrease in ROS production. ROS production is 
known to either stimulate or repress NFkB activity depending on phase and 
context (Lingappan, 2018). Nuclear factor-kappa B (NFkB) modulates the 
gene expression of a variety of cellular processes, such as; the innate 
immune response, cell proliferation, apoptosis and stress responses to a 
variety of toxic stimuli (Hayden and Ghosh, 2004). Under conditions, in 
which cellular production of ROS overwhelms the antioxidant response, a 
state of oxidative stress is induced (Kim et al., 2015). The NFkB pathway is 
known to possess anti-oxidant roles in conditions of oxidative stress. 
Evidence suggests NFkB plays a protective role, under oxidative stress 
conditions via inhibiting ROS accumulation (Djavaheri-Mergny et al., 2004). 
Results have previously shown that inhibiting NFkB results in an increase in 
TNF-induced ROS production, lipid peroxidation and protein oxidation 
(Djavaheri-Mergny et al., 2004). ROS signalling can trigger apoptosis 
depending on the severity of the oxidative stress, NFkB targets genes 
promoting cell survival via attenuation of ROS (Vallabhapurapu and Karin, 
2009). One of the ways by which NFkB affect ROS levels, is by increased 
levels of antioxidant genes, such as Manganese Superoxide Dismutase 
(MnSOD) (Kairisalo et al., 2007). The mitochondrial enzyme, MnSOD 
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protects cells from oxidative stress via conversion of O2- into H2O2 (Morgan 
and Liu, 2011). Previous studies into human endothelial cells have shown 
SIRT1 promotes the regulation of MnSOD expression, whilst increasing 
oxidative stress resistance (Zhang et al., 2017).  
ROS signalling has also been shown to play a complex intrinsic role in 
glycolytic activity (Kondoh et al., 2007). Increased mitochondrial ROS 
production is observed in various pathological conditions, a hallmark of the 
groups of diseases is enhanced glycolytic activity with low oxidative 
phosphorylation (Liemburg-Apers et al., 2015). A study found that in 
conditions of increased ROS production, mitochondria converted to the 
glycolytic pathway in order to reduce mitochondrial ROS levels (Liemburg-
Apers et al., 2015). Although conditions may favour glucose-stimulated 
ROS production, elevated levels of ROS may also be counterbalanced by 
endogenous antioxidant systems in conjunction with shift towards 
glycolysis (Liemburg-Apers et al., 2015).  
As previously stated, our results suggest a metabolic shift towards 
glycolysis of CLN7 NPCs as shown in 5.5. This change in the metabolic 
profile of the CLN7 NPCs resulted in an increase in ROS production, thus 
increase in oxidative stress. However, our results show CLN7 NPCs have 
significant decrease in HO-1 expression compared to healthy controls, with 
an increase in SIRT1 expression of 7.8-fold. Previous studies have found 
that in addition to a shift to glycolysis, a cell’s endogenous antioxidant 
response system may counterbalance the increase in ROS. This notion is 
supported by the increase in SIRT1 in CLN7 NPCs by 7.8-fold when 
compared to control NPCs. In conjunction, CLN7 NPCs display a 1.54-fold 
increase in NFkB expression than that of controls, with NFkB known to 
produce antioxidant effects by acting upon MnSOD and inhibiting ROS 
production.  
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6.0 Future Work 
The results from the project allow for the deduction of differences in 
metabolism and autophagic flux in CLN7 neural progenitor cells compared 
to controls. The results show promising progression into understanding the 
mechanisms and pathogenesis of CLN7 disease, however the data provides 
a strong foundation for further research. Although the production of CLN7 
neurons was successful during the project there were issues regarding cell 
death in terminal differentiation. Currently, most neural differentiation 
protocols are time consuming and inefficient, future research should aim 
to drastically improve the efficiency of the protocols.  
Our results demonstrated a metabolic shift towards glycolysis in neural 
progenitor cells of CLN7 compared to controls; however, it was not clear 
the mechanisms in which this occurred. This clearly shows the need for 
additional research into the relationship between OXPHOS and glycolysis in 
CLN7 NPCs and subsequent neuronal cells. A suggested method for 
measuring the rate of glycolysis within our CLN7 NPCs compared against 
controls would be to measure the glucose uptake and lactate production of 
each cell type using our in-house Agilent, SeahorseXF Analyzer. Glycolytic 
flux of a cell in culture can be measured via the measurement of glucose 
uptake and the excretion of lactate into the surrounding media. This 
further analysis would be of great use in providing further insight into the 
metabolic shift of CLN7 NPCs.  
As well as measuring glycolytic flux, the SeahorseXF Analyzer is capable of 
measuring oxidative stress in cell in culture. The Seahorse XF Cell Mito 
Stress Kit is optimized for assessing mitochondrial function, with multiple 
parameters obtained in one assay such as; basal respiration, ATP 
production-coupled respiration, maximal and reserve capacities and non-
mitochondrial respiration. The analysis provides insights into mitochondrial 
dysfunction and permits investigation into functional differences between 
cell types. Our results suggest an increase in SIRT1 as a response to 
oxidative stress, Seahorse oxidative stress analysis would be of great use to 
support our results.  
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We were able to deduce differences in autophagic flux through the 
utilization of western blot, further analysis into accumulation into proteins 
such as microtubule-associated protein light chain-II (LC3-II) and LAMP1 
would be of great use in providing further evidence of autophagic 
impairment.   
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7.0 Appendix 
7.1 Terminal differentiation of CLN7 NPCs 
Figure 30: Terminal differentiation images of CLN7 NPCs.  
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7.2 RT-PCR Analysis of NPCs 
Prior to qPCR analysis, RT-PCR was implemented initially in order to qualitatively 
assess differences in expression of various genes in CLN7 NPCs compared to 
controls. Once data had been collected, quantitative PCR was implemented for a 
more accurate measurement of gene expression. Images below depict results 
obtained.  
 
Table 20: RT-PCR Primers 
Target Forward Primer Reverse Primer 
Endogenous OCT4 GCGATCAAGCAGCGACT TTCACCTTCCCTCCAACC 
Endogenous SOX2 CATGTCCCAGCACTACCAGA GGGTTTTCTCCATGCTGTTT 
Endogenous LIN28 TGTCCAAATGCAAGTGAG GCAGGTTGTAGGGTGATTCC 
Nanog TTTGTGGGCCTGAAGAAAACT AGGGCTGTCCTGAATAAGCAG 
E-cadherin TGCCCAGAAAATGAAAAAG GTGTATGTGGCAATGCGTTC 
GAPDH ATGTTCGTCATGGGTGTGAA GGTGCTAAGCAGTTGGTGGT 
GLUT1 AACTCTTCAGCCAGGGTCCAC CACAGTGAAGATGATGAAGAC 
SIRT1 TAGCCTTGTCAGATAAGGAAGGA ACAGCTTCACAGTCAACTTTGT 
Nestin GGCAGCGTTGGAACAGAG CATCTTGAGGTGCGCCAGCT 
RN18S1 ACACGGACAGGATTGACAGA GGACATCTAAGGGCATCACAG 
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Figure 31:: RT-PCR Analysis in NPCs Supplementary Data 
 
 
 
 
 
 
 
 
Figure depicts RT-PCR products of; (2) CLN7 (474) NPC, (3) Control NPC, (4) CLN7 iPSC, (5) 
Control iPSC, (6) HEK293, (7) Shef3 ESC and (8) No-RT ran along a 2% agarose gel 
supplemented with GelRed at 15V for 1 hour for qualitative analysis of GAPDH marker. 
Secondary image displays PCR product of RN18S1 housekeeper.  
 
 
 
 
 
 
 
Figure depicts RT-PCR products of; (2) CLN7 (474) NPC, (3) Control NPC, (4) CLN7 iPSC, (5) 
Control iPSC, (6) HEK293, (7) Shef3 ESC and (8) No-RT ran along a 2% agarose gel 
supplemented with GelRed at 15V for 1 hour for qualitative analysis of GLUT1 marker. 
Secondary image displays PCR product of RN18S1 housekeeper.  
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Figure depicts RT-PCR products of; (2) CLN7 (474) NPC, (3) Control NPC, (4) CLN7 iPSC, (5) 
Control iPSC, (6) HEK293, (7) Shef3 ESC and (8) No-RT ran along a 2% agarose gel 
supplemented with GelRed at 15V for 1 hour for qualitative analysis of OCT4 pluripotency 
marker. Secondary image displays PCR product of RN18S1 housekeeper.  
 
 
 
 
 
 
 
 
 
 
Figure depicts RT-PCR products of; (2) CLN7 (474) NPC, (3) Control NPC, (4) CLN7 iPSC, (5) 
Control iPSC, (6) HEK293, (7) Shef3 ESC and (8) No-RT ran along a 2% agarose gel 
supplemented with GelRed at 15V for 1 hour for qualitative analysis of LIN28 pluripotency 
marker. Secondary image displays PCR product of RN18S1 housekeeper.  
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Figure depicts RT-PCR products of; (2) CLN7 (474) NPC, (3) Control NPC, (4) CLN7 iPSC, (5) 
Control iPSC, (6) HEK293, (7) Shef3 ESC and (8) No-RT ran along a 2% agarose gel 
supplemented with GelRed at 15V for 1 hour for qualitative analysis of SOX2 pluripotency 
marker. Secondary image displays PCR product of RN18S1 housekeeper.  
 
 
 
 
 
 
 
 
 
Figure depicts RT-PCR products of; (2) CLN7 (474) NPC, (3) Control NPC, (4) CLN7 iPSC, (5) 
Control iPSC, (6) HEK293, (7) Shef3 ESC and (8) No-RT ran along a 2% agarose gel 
supplemented with GelRed at 15V for 1 hour for qualitative analysis of Nanog marker. 
Secondary image displays PCR product of RN18S1 housekeeper.  
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Figure depicts RT-PCR products of; (2) CLN7 (474) NPC, (3) Control NPC, (4) CLN7 iPSC, (5) 
Control iPSC, (6) HEK293, (7) Shef3 ESC and (8) No-RT ran along a 2% agarose gel 
supplemented with GelRed at 15V for 1 hour for qualitative analysis of E-cadherin marker. 
Secondary image displays PCR product of RN18S1 housekeeper.  
 
 
 
 
 
 
 
 
 
Figure depicts RT-PCR products of; (2) CLN7 (474) NPC, (3) Control NPC, (4) CLN7 iPSC, (5) 
Control iPSC, (6) HEK293, (7) Shef3 ESC and (8) No-RT ran along a 2% agarose gel 
supplemented with GelRed at 15V for 1 hour for qualitative analysis of Nestin marker. 
Secondary image displays PCR product of RN18S1 housekeeper.  
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LDHA 
 
 
 
 
 
 
 
 
 
 
 
Figure 32: qPCR Analysis of LDHA in NPCs 
Figure 31. Differential expression of LDHA between CLN7 neural progenitor cells 
(NPCs) in comparison to healthy counterpart. Relative expression was determined 
of CLN7 NPCs against control cell. Subsequently an Independent T-Test was 
performed in order to determine significance between the two cell types, in 
which a value of p=0.34 was obtained, displaying no significance between the two 
data sets. The graph depicts the relative expression of three biological repeats 
with each repeat also involving three technical repeats. Subsequently, error bars 
are calculated based on the standard error mean (SEM) of each NPC sample.  
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UCP2 
 
 
 
 
 
 
 
 
 
Figure 33: qPCR Analysis of UCP2 in NPCs  
Figure 32. Differential expression of the metabolic stress marker, UCP2 between 
CLN7 neural progenitor cells (NPCs) in comparison to healthy counterpart. 
Relative expression was determined of CLN7 NPCs against control cell. 
Subsequently an Independent T-Test was performed in order to determine 
significance between the two cell types, in which a value of p=0.23 was obtained, 
displaying no significance between the two data sets. The graph depicts the 
relative expression of three biological repeats with each repeat also involving 
three technical repeats. Subsequently, error bars are calculated based on the 
standard error mean (SEM) of each NPC sample.  
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GLUT1 
 
 
 
 
 
 
 
 
Figure 34: qPCR Analysis of GLUT1 in iPSCs 
Figure 33. Differential expression of GLUT1 between CLN7 induced pluripotent 
stem cells in comparison to healthy counterpart control iPSC as well as Shef3 
embryonic stem cells and HEK293 cells. Subsequently, single factor ANOVAs 
were performed with post-hoc Tukey analysis performed in order to 
determine statistical significance between groups. It was determined there 
was no statistical differences between CLN7 iPSCs and controls with a value 
of p=0.58 obtained, displaying no significance between the two data sets. 
Conversely, no statistical difference was found between control iPSCs and Shef3 
with p=0.067 calculated, CLN7 to Shef3 was calculated at p=0.063 also displaying 
statistical significance. The graph depicts the relative expression of three 
biological repeats with each repeat also involving three technical repeats. 
Subsequently, error bars are calculated based on the standard error mean (SEM) 
of each iPSC sample.  
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SIRT1 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 35: qPCR Analysis of SIRT1 in iPSCs 
Figure 34. Differential expression of SIRT1 between CLN7 induced pluripotent 
stem cells in comparison to healthy counterpart control iPSC as well as Shef3 
embryonic stem cells and HEK293 cells. Subsequently, single factor ANOVAs 
were performed with post-hoc Tukey analysis performed in order to 
determine statistical significance between groups. It was determined there 
was no statistical differences between CLN7 iPSCs and controls with a value 
of p=0.24 obtained, displaying no significance between the two data sets. 
Conversely, no statistical difference was found between control iPSCs and Shef3 
with p=0.52 calculated, CLN7 to Shef3 was calculated at p=0.43 also displaying 
statistical significance. The graph depicts the relative expression of three 
biological repeats with each repeat also involving three technical repeats. 
Subsequently, error bars are calculated based on the standard error mean (SEM) 
of each iPSC sample.  
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7.3 Western Blot Technical Repeats 
 
Figure 36: Western Blot Technical Repeats  
Technical Repeats for p70:  
 
 
 
 
 
 
 
 
 
Technical Repeats for p-p70: 
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Technical Repeats for -actin: 
 
 
 
 
 
 
 
 
 
 
 
Technical Repeats for p62: 
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7.4 qPCR Primers 
Table 21: qPCR primer set 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Target Forward Primer Reverse Primer Amplicon 
size (bp) 
LIN28A AGCGCAGATCAAAAGGAGACA CCTCTCGAAAGTAGGTTGGCT 189 
SOX2 GACCAGCTCGCAGACCTACAT TGGAGTGGGAGGAAGAGGTA 155 
NESTIN GGCAGCGTTGGAACAGAG CATCTTGAGGTGCGCCAGCT 163 
NFkB1 TGCCAACAGATGGCCCATAC TGTTCTTTTCACTAGAGCCACCA 123 
HO-1 CGGGACCTGACTGACTACC TGAAGGTAGTTTCGTGCATGC 292 
PKM2 ATGTCGAAGCCCCATAGTGAA TGGGTGGTGAATCAATGTCCA 118 
UCP2 CCCCGAAGCCTCTACAATGG CTGAGCTTGGAATCGGACCTT 219 
ATP 
SYNTHASE 
CTTGACCTTCTTTGCGGCTC CGCACGGACAGCATCTTTG 102 
GLUT1 AACTCTTCAGCCAGGGTCCAC CACAGTGAAGATGATGAAGAC 140 
LDHA ATGGCAACTCTAAAGGATCAGC CCAACCCCAACAACTGTAATCT 86 
SIRT1 AAGTTGACTGTGAAGCTGTACG TGCTACTGGTCTTACTTTGAGGG 218 
PABC4 
 
GCTCAGGGAAGGCCTCCAT GAGCGCTCAGCAGCAGCAACAG 
 
260 
 
104 | P a g e  
 
 
7.5 Supplementary Immunocytochemistry for Neuronal Cells  
Figure 37: Supplementary ICC Data for Neuronal Cells  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Supplementary immunocytochemistry images produced depicts CLN7 neurons developed 
through terminal differentiation of neural progenitor cells. Neuronal cells were incubated 
with LAMP1 (green) and p62 (red) primary antibody at a dilution of 1:200 for a minimum 
of ~12 hours at 4OC, followed by the incubation of Alexa Fluor rabbit and mouse 
secondary antibodies, respectively. Following this, cells were also incubated with DNA 
stain, DAPI in order to visualize nucleus. Arrows show the accumulation of LAMP1 (green) 
in the axons of the neurons, whilst arrows directed towards p62 (red) display 
accumulation within vesicles, an indicator of impaired autophagy. Images shown at x20 
magnification, whilst scale bar displayed at 100m.  
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Supplementary immunocytochemistry images produced depicts CLN7 neurons developed 
through terminal differentiation of neural progenitor cells. Neuronal cells were incubated 
with LAMP1 (green) and at a dilution of 1:200 for a minimum of ~12 hours at 4OC, 
followed by the incubation of Alexa Fluor rabbit secondary antibody in addition to 
incubation of MitoTracker (red), in order to assess mitochondria utilizing mitochondrial 
membrane potential. Following this, cells were also incubated with DNA stain, DAPI in 
order to visualize nucleus. White arrows show the accumulation of LAMP1 (green) in the 
axons of the neurons, whilst yellow arrows directed towards MitoTracker (red) within 
mitochondria. Images shown at x20 magnification, whilst scale bar displayed at 100m.  
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